1 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 Phase I Placebo -Controlled Study of the Infectivity, Safety and Immunogenicity of a 
Single Dose of a Recombinant Live- attenuated Respi[INVESTIGATOR_322011],  
RSV 6120/ ∆NS2 /1030s, Lot RSV#012A, Delivered as Nose Drops to  
RSV-Seropositive Children 12 to 59 Months of Age and  
RSV-Seronegative Infants and Children 6 to 24 Months of Age  
 
Sponsored by:  
[CONTACT_4461] (NIAID)  
 
Center for Immunization Research (CIR) Protocol Number: CIR 322 
Western IRB Protocol Number: WIRB #  20172138 
FDA Investigational New Drug ( IND) Number:  [ADDRESS_1119734] Assurance:  FWA #00000287 
 
IND Sponsor:   
Office of Clinical Research Policy and Regulatory Operations (OCRPRO ) 
Division of Clinical Research (DCR)  
National Institute of Allergy and Infectious Diseases (NIAID) 
National Institutes of Health (NIH)  
[ADDRESS_1119735] 
Room 4B11, MSC 9820 
Bethesda, MD [ZIP_CODE] 
  
Respi[INVESTIGATOR_14250] (RSV ) 6120/∆NS2/1030s 
Provided by: 
[CONTACT_4462] (LID), NIAID, NIH  
 
Medical Monitor:  
Shirley Jankelevich, MD 
 
Principal Investigator:  
[INVESTIGATOR_322012], MD  
 
Version 3.0 
April 6, 2020 
 
  
 
 
  The information contained herein is the property of the NIAID and may not be reproduced, published 
or disclosed to others without the written authorization of the NIAID.  
2 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119736] 
Johns Hopkins Bloomberg School of Public Health (JHSPH)  
[ADDRESS_1119737], Room 217  
Baltimore, MD [ZIP_CODE]  
Phone: [PHONE_6768] 
Administrative Coordinator: [PHONE_6769]  
Email: [EMAIL_6320]  
 
CLINICAL INVESTIGATORS  
Kawsar Talaat, MD  
CIR, JHSPH  
[ADDRESS_1119738], Room 249  
Baltimore, MD [ZIP_CODE]  
Phone: [PHONE_009]  
Email: [EMAIL_6325] 
  
Kristi Herbert, CRNP -P  
CIR, JHSPH  
[ADDRESS_1119739], Room 205  
Baltimore, MD [ZIP_CODE]  
Phone: [PHONE_6778]  
Email: [EMAIL_6326]  
 
Elizabeth Schappell, RN, MSN, CCRP  
CIR, JHSPH  
[ADDRESS_1119740], Room 205  
Baltimore, MD [ZIP_CODE]  
Phone: [PHONE_6779]  
Email: [EMAIL_6327]  
 Jocelyn San Mateo, CRNP -F, CCRP  
CIR, JHSPH  
[ADDRESS_1119741], Room 201  
Baltimore, MD [ZIP_CODE]  
Phone: [PHONE_6780]  
Email: [EMAIL_6328]  
Beulah Sabundayo, PharmD, MPH  
CIR, JHSPH  
[ADDRESS_1119742], Room 200  
Baltimor e, MD [ZIP_CODE]  
Phone: [PHONE_011]  
Email: [EMAIL_6329]  
 Suzanne Woods, CRNP -P, CCRP  
CIR, JHSPH  
[ADDRESS_1119743], Room 212  
Baltimore, MD [ZIP_CODE]  
Phone: [PHONE_6781]  Cell: 443 -813-0697
 
Email: [EMAIL_6330]  
 
SCIENTIFIC INVESTIGATORS    
Ursula Buchholz, PhD  
LID, NIAID, NIH  
Building 50, Room [ADDRESS_1119744], MSC 8007  
Bethesda, MD [ZIP_CODE]  
Phone: [PHONE_6783]  
Email: [EMAIL_6331]  
  
Peter Collins, PhD  
LID, NIAID, NIH  
Building 50, Room [ADDRESS_1119745], MSC 8007  
Bethesda, MD [ZIP_CODE]  
Phone: [PHONE_16895]  
Email: [EMAIL_15383]  
 
3 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119746], Room 117  
Baltimore, MD [ZIP_CODE]  
Phone: [PHONE_16896]  
 CLINICAL LABORATORIES   
Johns Hopkins Hospi[INVESTIGATOR_809704]  
[ADDRESS_1119747]  
Baltimore, MD [ZIP_CODE]  
Phone: [PHONE_16897]  
 
Center for Immunization Research East  
Johns Hopkins Bayview Medical Center  Campus
 
[ADDRESS_1119748]  
Baltimore, MD [ZIP_CODE]  
Phone: [PHONE_017]  
 
Center for Immunization Research South  
[ADDRESS_1119749]  
Baltimore, MD [ZIP_CODE]  
Phone: [PHONE_16898] 
VIROLOGY /IMMUNOLOGY LABORATORIES  
CIR Laboratories  
[ADDRESS_1119750], Room E5402  
Baltimore, MD [ZIP_CODE]  
Phone: [PHONE_018]  INSTITUTIONAL REVIEW BOARD   
Western Institutional Review Board® (WIRB ) 
[ADDRESS_1119751] SE Suite 120  
Puyallup, WA [ZIP_CODE]  
Phone: [PHONE_6786] or [PHONE_3665]  I
NSTITUTIONAL BIOSAFETY OFFICE (IBC) 
[ADDRESS_1119752]  
Room 4B11, MSC 9820 Bethesda, MD [ZIP_CODE]
 
Phone: [PHONE_16899]  
Email: [EMAIL_15384]  
 SPONSOR MEDICAL MONITOR  
Shirley Jankelevich, MD Medical Monitor Clinical Monitoring Research Program Leidos Biomedical Research, Inc.  
[ADDRESS_1119753], Room 248  
Frederick, Maryland   [ZIP_CODE] 
Phone [PHONE_015] Email: [EMAIL_3332]
 
 
  
4 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119754] RSV  .................................................................................................... 16 
[IP_ADDRESS]  RSV Vaccine Candidates with an NS2 Deletion  ........................................................................................... 17  
1.2.2  Preclinical Studies  ................................................................................................................................ 18 
[IP_ADDRESS]  Temperature sensitivity of RSV 6120/ΔNS2/1030s  ...................................................................................... 18  
[IP_ADDRESS]  Replication of an experimental lot of RSV 6120/ΔNS2/1030s  in an in -vitro model of mucociliary normal 
human tracheal/bronchial epi[INVESTIGATOR_1663]  ......................................................................................................................... 18  
[IP_ADDRESS]  Replication of experimental lot and CTM of RSV 6120/ΔNS2/1030s in African green monkeys (AGMs)  . 20 
1.2.3  Previous Clinical Experience  ............................................................................................................... 20 
 RATIONALE  ................................................................................................................................................. 21 
 CLINICAL DEVELOPMENT PLAN .................................................................................................................. 21 
 HYPOTHESES  ............................................................................................................................................... 21 
 OBJECTIVES  ................................................................................................................................................... 21 
2.1. PRIMARY OBJECTIVES ................................................................................................................................. 21 
2.2. SECONDARY OBJECTIVES  ............................................................................................................................ 22 
2.3. EXPLORATORY OBJECTIVE  ......................................................................................................................... 22 
 STUDY DESIGN  ............................................................................................................................................. 22 
 STUDY POPULATION  ................................................................................................................................... 23 
 INCLUSION CRITERIA FOR RSV -SEROPOSITIVE CHILDREN  ......................................................................... 24 
 EXCLUSION CRITERIA FOR RSV -SEROPOSITIVE CHILDREN  ........................................................................ 24 
 INCLUSION CRITERIA FOR RSV -SERONEGATIVE INFANTS & CHILDREN  ..................................................... 26 
 EXCLUSION CRITERIA FOR RSV -SERONEGATIVE INFANTS & CHILDREN  .................................................... [ADDRESS_1119755] FORMULATION  ................................................................................................................ 30 
5.2.1  RSV 6120/∆NS2/1030s  ........................................................................................................................ 30 
5 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 5.2.2  Diluent for RSV 6120/∆NS2/1030s  ..................................................................................................... 30 
5.2.3  Placebo for RSV 6120/∆NS2/1030s  ..................................................................................................... [ADDRESS_1119756] PREPARATION  ................................................................................................................. 31 
5.4.1  Diluent .................................................................................................................................................. 31 
5.4.2  Placebo  ................................................................................................................................................. 31 
5.4.3  Live RSV 6120/∆NS2/1030s  ................................................................................................................ [ADDRESS_1119757] ACCOUNTABILITY  ........................................................................................................... 32 
 DISPOSITION OF USED/UNUSED STUDY PRODUCT  ...................................................................................... 33 
 FINAL DISPOSITION OF STUDY PRODUCTS  .................................................................................................. 33 
 CONCOMITANT MEDICATIONS  .................................................................................................................... 33 
 STUDY VISITS AND PROCEDURES  ........................................................................................................... 33 
 CONSENTING PROCESS  ................................................................................................................................ 35 
 SCREENING VISIT ........................................................................................................................................ 35 
6.2.1  Participants Enrolled in Surveillance for a Second RSV Season  ......................................................... 36 
 RANDOMIZATION  ........................................................................................................................................ 36 
 ENROLLMENT  ............................................................................................................................................. 37 
6.4.1  Enrollment - Inoculation (Day 0)  ......................................................................................................... 37 
6.4.2  Enrollment in the Second Season of RSV Surveillance (Group 2 Only) .............................................. 39 
 STUDY PHASES  ........................................................................................................................................... 39 
6.5.1  RSV -Seropositive Children (Group 1)  ................................................................................................. 39 
[IP_ADDRESS]  Acute Phase: In -person Study Visit Days  ..................................................................................................... 39  
[IP_ADDRESS]  Acute Phase: Non -Visit Study Day Contacts  ................................................................................................ 40  
[IP_ADDRESS]  Study Day 11  ................................................................................................................................................ 40  
[IP_ADDRESS]  Post-Acute Phase .......................................................................................................................................... 41  
[IP_ADDRESS]  Study Day 28 Visit  ........................................................................................................................................ 41  
6.5.2  RSV -Seronegative Infants and Children  .............................................................................................. 41 
[IP_ADDRESS]  Acute Phase: In -person Study Visit Days  ..................................................................................................... 41  
[IP_ADDRESS]  Acute Phase: Non -Visit Study Day Contacts  ................................................................................................ 42  
[IP_ADDRESS]  Study Day 29  ................................................................................................................................................ 43  
[IP_ADDRESS]  Post-Acute Phase .......................................................................................................................................... 43  
[IP_ADDRESS]  Study Day 56 Visit  ........................................................................................................................................ 43  
[IP_ADDRESS]  Period after Day [ADDRESS_1119758] ..................................................................................................... 44  
 RSV  SURVEILLANCE : FIRST SEASON  .......................................................................................................... [ADDRESS_1119759]-RSV  Season Surveillance Study Visit  .......................................................................................... 46 
 RSV  SURVEILLANCE : SECOND SEASON  ...................................................................................................... [ADDRESS_1119760] Containment  ........................................................................................................................ 50 
 SAFETY ASSESSMENT, MONITORING, AND REPORTING ................................................................... 50 
 SAFETY -RELATED ROLES AND RESPONSIBILITIES ....................................................................................... 50 
6 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 7.1.1  Principal Investigator  ........................................................................................................................... 50 
7.1.2  Safety Review and Communications Plan (SRCP) and Transfer of Regulatory Obligations (TORO)  [ADDRESS_1119761] KEEPI[INVESTIGATOR_1645]  ............................................................................................. 67 
 DATA MANAGEMENT RESPONSIBILITIES  .................................................................................................... 67 
 ESSENTIAL AND SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA ..................................................... 68 
 CLINICAL INVESTIGATOR ’S BROCHURE  ...................................................................................................... [ADDRESS_1119762] /ETHICS COMMITTEE REVIEW AND APPROVAL  ......................................... [ADDRESS_1119763]  ...................................................................................................................... 70 
7 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 
 REIMBURSEMENT /COMPENSATION  ............................................................................................................. 71 
12.6.1  Study Compensation: Acute Phase and First Season Surveillance  ....................................................... 71 
12.6.2  Study Compensation: Second Season Surveillance  .............................................................................. 71 
 PRIVACY AND CONFIDENTIALITY ................................................................................................................ 71 
 MANAGEMENT OF INCIDENTAL FINDINGS  ................................................................................................... 71 
 ADMINISTRATIVE PROCEDURES .............................................................................................................. 71 
 REGULATORY OVERSIGHT  .......................................................................................................................... 71 
 PROTOCOL REGISTRATION  .......................................................................................................................... 72 
 STUDY IMPLEMENTATION  ........................................................................................................................... 72 
 PROTOCOL DEVIATION REPORTING  ............................................................................................................ 72 
 CLINICAL TRIALS .GOV  ................................................................................................................................. 72 
 PUBLICATIONS  .............................................................................................................................................. 72 
 REFERENCES  ................................................................................................................................................. 73 
APPENDICES  ............................................................................................................................................................. 77 
APPENDIX I: TABLES  REFERENCED IN THE BACKGROUND SECTION  ....................................................... 77 
APPENDIX II: SCHEDULE OF EVENTS: SCREENING, ACUTE PHASE, AND POST- ACUTE PHASE  .......... 80 
APPENDIX III: SCHEDULE OF EVENTS: RSV SEASONAL SURVEILLANCE  ................................................. 82 
APPENDIX IV: DEFINITIONS OF SOLICITED ADVERSE EVENTS  .................................................................. 83 
APPENDIX V: RSV SEASONALITY IN BALTIMORE  .......................................................................................... 84 
 
 
  
8 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119764] OF TABLES  
 
Table 1: Inoculation Schedule .......................................................................................................13  
Table 2: Temperature Sensitivity of Experimental Lots of RSV 6120/ΔNS2/1030s and RSV 
ΔNS2/Δ1313/I1314L ......................................................................................................18  
Table 3: Screening Visit Procedures ..............................................................................................36  
Table 4: Enrollment Visit Procedures  ............................................................................................38  
Table 5: Acute Phase In -Person Visit Procedures – RSV -Seropositive Children .........................39  
Table 6: Acute Phase Non -Visit Contact [CONTACT_322096] – RSV -Seropositive Children ....................40  
Table 7: Day 11 Non- Visit Procedures – RSV -Seropositive Children ..........................................40  
Table 8: Day 28 Visit Procedures – RSV -Seropositive Children ..................................................41  
Table 9: Acute Phase In -Person Visit Procedures – RSV -Seronegative Children ........................42  
Table 10: Acute Phase Non -Visit Contact [CONTACT_322096] – RSV -Seronegative Children  .................42  
Table 11: Day 29 Non- Visit Procedures – RSV -Seronegative Children .......................................43  
Table 12: Day 56 Visit Procedures – RSV -Seronegative Children ...............................................44  
Table 13: Pre-RSV Season Surveillance Study Visit Procedures ..................................................45  
Table 14: RSV Season Surveillance Procedures  ...........................................................................45  
Table 15: Post-RSV Seasonal Surveillance Study Visit Procedures .............................................46  
Table 16: Illness Visit Timeframe  .................................................................................................47  
Table 17: Illness Visit Procedures .................................................................................................47  
Table 18: Early Discontinuation Procedures .................................................................................48  
Table 19: AE CRF Recording Requirements for RSV-Seropositive Subjects ..............................53  
Table 20: AE CRF Recording Requirements for RSV- Seronegative Subjects  .............................54  
Table 21: Grading for Adverse Events ..........................................................................................59  
Table 22: Grading for Fever ..........................................................................................................60  
Table 23: Pausing and Stoppi[INVESTIGATOR_1869] ..........................................................................................60  
Table 24: The Probability of Observing LRI Events in Seronegative Vaccine Recipi[INVESTIGATOR_840] ...........63  
Table 25: Percent of Participants Experiencing LRI or AEs with Exact 90% CI..........................63  
Table 26: Magnitude of Difference in Responses Detectable with 80% Power  ............................64  
Table 27: Viral Titers of Nasopharyngeal Swab Samples from AGMs Inoculated with the 
Experimental  Lot or CTM of RSV 6120/ΔNS2/1030s, with RSV ΔNS2/Δ1313/I1314L, 
or with Recombinant wt RSV rA2 ..................................................................................77  
Table 28: Viral Titer of Tracheal Lavage Samples from AGMs Inoculated with the Experimental 
Lot or CTM of RSV 6120/ΔNS2/1030s, with RSV ΔNS2/Δ1313/I1314L, or with 
Recombinant wt RSV rA2 ..............................................................................................78  
Table 29: Serum PRNT 60 Titers in AGMs Inoculated with the Experimental Lot or with CTM of 
RSV 6120/ΔNS2/1030s or RSV ΔNS2/Δ1313/I1314L, or Recombinant wt RSV rA2 .79  
Table 30: Schedule of Events: Group 1: RSV- Seropositive Participants  ......................................80  
Table 31: Schedule of Events: Group 2: RSV- Seronegative Participants  .....................................81  
Table 32: Schedule of Events: RSV Seasonal Surveillance  ..........................................................82  
Table 33: Definitions of Solicited Adverse Events ........................................................................83  
 
  
9 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119765] OF FIGURES  
 
Figure 1: Group 1 – Study Overview .............................................................................................14  
Figure 2: Group 2 – Study Overview .............................................................................................14  
Figure 3: Multicycle Replication of Experimental Lots in an in -vitro Model of Normal Human 
Bronchial/Tracheal Epi[INVESTIGATOR_7032]  ................................................................................19  
Figure 4: Investigational Product Label Sample ............................................................................30  
Figure 5: Power Curves for Assessment of Vaccine Virus Shedding in RSV seronegative 
Vaccinees  ........................................................................................................................64  
Figure 6: RSV Seasonality in Baltimore  ........................................................................................84  
 
 
 
 
  
  
10 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119766] OF ABBREVIATIONS  
 
ACIP  
AE Advisory Committee on Immunization Practices (CDC)  
adverse event  
AGM  African green monkey  
AIDS  acquired immunodeficiency syndrome  
BSC  biologic safety cabinet  
CACI  compounding aseptic containment isolator  
CDC  Centers for Disease Control  and Prevention  
cDNA  complementary deoxyribonucleic acid  
CFR  Code of Federal Regulations  
CGMP  Current Good Manufacturing Practice  
CI confidence interval  
CIR Center for Immunization Research  
CL clinical lot  
cp cold-passaged  
CRADA  Cooperative Research and Development Agreement  
CRF  case report form  
CRL  Charles River Laboratories  
CSO  Clinical Safety Office  
CTM  clinical trial material  
DAERS  DAIDS Adverse Event Reporting System  
DAIDS  Division of AIDS  
DAIDS PRO  Division of AIDS Protocol Registration Office  
DC discontinuation  
DCR  Division of Clinical Research  
DHHS  Department of Health and Human Services  
DMC  Data Management Center  
DMEM  Dulbecco’s Modified Eagle Medium  
DNA  deoxyribonucleic acid  
DSMB  Data and Safety Monitoring Board  
EAE  expedited adverse event  
EENT  ears, eyes, nose, throat  
ELISA  enzyme -linked immunosorbent assay  
F protein  fusion protein  
FDA  Food and Drug Administration  
FDAAA  Food and Drug Administration Amendments Act of 2007  
FSTRF  Frontier Science & Technology Research Foundation, Inc.  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
GMP  Good Manufacturing Practice  
GMT  geometric mean titer  
HIPAA  Health Insurance Portability and Accountability Act  
HIV human immunodeficiency virus  
HJF Henry M. Jackson Foundation for the Advancement of Military Medicine  
IB investigator’s brochure  
ICD informed  consent document  
ICH International Conference on Harmoni sation  
IgA, IgG, IgE  immunoglobulin A, G, E  
IMPAACT  International Maternal Pediatric Adolescent AIDS Clinical Trials Network  
i.n. intranasally  
IND investigational new drug  
11 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119767]  
MA-LRI medically attended lower respi[INVESTIGATOR_809705] & Regulatory Operations  
OHRP  Office for Human Research Protections  
ORF  open reading frame  
OTC  over-the-counter  
PBMC  peripheral blood mononuclear cell  
PCR  polymerase chain reaction  
PE physical examination  
PFU plaque -forming units 
PI [INVESTIGATOR_809706]  
r recombinant  
RE regulatory entity  
RNA  ribonucleic acid  
rRT-PCR reverse transcription polymerase chain reaction  
RSC  Regulatory Support Center  
RSV  respi[INVESTIGATOR_809707]-qPCR quantitative reverse transcription polymerase chain reaction  
SAE  serious adverse event  
SAM  synthetic absorptive matrix  
SDAC  Statistical & Data Analysis Center, Harvard School of Public Health  
SDMC  Statistical and Data Management Center  
SERF  Safety Expedited Report Form  
SES subject  enrollment system  
SID study identification number  
SMM  sponsor medical monitor  
SOP standard operating procedure  
SPG sucrose -phosphate -glutamate buffer  
SRCP  Safety Review and Communication Plan  
S[LOCATION_003]R  serious, unexpected, suspected adverse reaction  
TL tracheal lavage  
ts temperature sensitivity  
TSH shut-off temperature  
TSP small plaque temperature  
12 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119768]  
wt wild-type 
∆M2 -2 deleted M2 -2 
  
  
13 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 PROTOCOL SUMMARY 
 
Phase I Placebo -Controlled Study of the Infectivity, Safety and Immunogenicity of a 
Single Dose of a Recombinant Live- attenuated Respi[INVESTIGATOR_322011],  
RSV 6120/∆NS2/1030s, Lot RSV#012A, Delivered as Nose Drops to  
RSV-Seropositive Children 12 to 59 Months of Age and RSV -Seronegative Infants  and 
Children 6 to 24 Months of Age 
 S
HORT TITLE   RSV 6120/∆NS2/1030s 
 
PURPOSE  To determine whether study vaccine is attenuated  and immunogenic in this age 
group 
 
DESIGN  A double blind, randomized, placebo-controlled study design will be used to 
evaluate the safety and immunogenicity of the study product  in 
RSV- seropositive and RSV -seronegative participants.  
 
STUDY POPULATION  Group 1 : Healthy RSV -seropositive* children ≥ 12 months to < 60  months of age  
 Group 2: Healthy RSV-seronegative^ infants and children ≥ 6 months to < 25 months of age  
 
*RSV-seropositive: RSV serum neutralizing antibody titer ≥ 1:40 ;  
  determined prior to inoculation and within the calendar year of inoculation  
  
^RSV -seronegative: RSV serum neutralizing antibody titer < 1:40;  
  determined ≤ 42 days prior to inoculation  
 
SAMPLE SIZE Group 1: Approximately 15 RSV- seropositive children  
Group 2: Approximately 21-[ADDRESS_1119769]  Single dose of intranasal RSV 6120/∆NS2/1030s vaccine or placebo 
 
Table 1: Inoculation Schedule  
 
 
 
   
  
*plaque -forming unit s (PFU) 
 
The study w ill start with group 1 and proceed to group 2 if there are not more than 2 vaccine -associated 
solicited  adverse events (AEs)  (Days 0 through 10)  and no vaccine- associated lower respi[INVESTIGATOR_10711] 
(LRI s) (Days 0 th rough 28) in RSV -seropositive children. If 3 or more RSV -seropositive  children (group 
1) have respi[INVESTIGATOR_809708] > 102.5 PFU  of vaccine virus as 
detected by [CONTACT_921], then we will evaluate the safety, infectivity, and immunogenicity of the vaccine virus 
in an additional 15 RSV -seropositive children before determining whether to continue with group 2.   
 Group #  N Study Product  Dose  
1 10 RSV 6120/∆NS2/1030s  105.7 PFU* 
5 Placebo  0 
2 14-20 RSV 6120/∆NS2/1030s  105.0 PFU* 
7-10 Placebo  0 
14 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119770]–RSV season visit . 
 
After the first season of RSV surveillance is completed, research staff may  invite the families of 
participants in group 2 t o participate in a n optional seco nd season of RSV surveillance during November-
March of the se cond year following enrollment.  
 
Figure 1: Group 1 – S tudy Overview  
 
 
Figure 2: Group 2  – Study Overview  
 
*Post- RSV Season specimens to be collected beginning April 1st  

15 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 
 BACKGROUND AND SCIENTIFIC RATIONALE   
 
 BACKGROUND  
 
1.1.1 Epi[INVESTIGATOR_623], Disease Burden, and the Need for a Vaccine 
 
In the [LOCATION_002] alone, RSV is responsible for 75,000 to 125,000 hospi[INVESTIGATOR_809709]  (1), and worldwide, RSV infects at least 34 million children under 5 years  old, resulting in  
an estimated 3.4 million RSV LRI hospi[INVESTIGATOR_4355] 66,000 to 199,000 RSV- attributable 
deaths each year (2). In temperate climates, annual RSV epi[INVESTIGATOR_809710], and nearly all children are infected within the first [ADDRESS_1119771] illness (URI), including rhinitis, pharyngiti s, and coryza, to 
severe LRI , including bronchiolitis and pneumonia. Beyond the acute burden of disease caused 
by [CONTACT_4510], severe RSV disease in infancy may predispose to reactive airway disease during childhood (3, 4). 
 
RSV is an enveloped RNA virus that is a member of the newly organized Pneumoviridae  family, 
genus Orthopneumovirus (5). RSV has a single negative-sense strand RNA genome of 15.2 
kilobases encoding 10 mRNAs. Each mRNA encodes a single protein, with the exception of the 
M2 mRNA, which contains 2 overlappi[INVESTIGATOR_809711]. The 11 RSV proteins are the viral RNA-binding 
nucleoprotein N, the phosphoprotein P, the large polymerase protein L, the attachment 
glycoprotein G, the fusion glycoprotein F, the small hydrophobic surface glycoprotein SH, the 
internal matrix protein M, the 2 nonstructural proteins NS1 and NS2, and the M2-1 and M2-2 
proteins encoded by [CONTACT_941] M2 mRNA. The gene order is: 3'- NS1-NS2-N-P-M- SH-G-F- M2-L-5'. 
RSV transcription and genome replication take place exclusively in the cytoplasm, and virions form by [CONTACT_322097][INVESTIGATOR_322018].  
 
Currently, no licensed vaccine against RSV is available, although there is broad consensus that 
such a vaccine is urgently needed and should be a global health priority. Although passive immunoprophylaxis with the monoclonal RSV- neutralizing antibody palivizumab (Synagis®; 
MedImmune) is available for high -risk infants, this approach is not feasible for general use. A 
formalin -inact ivated vaccine against RSV was evaluated clinically in the 1960s and did not 
confer protection; instead, disease enhancement occurred at a high rate following natural  
infection of vaccinees with wild-type ( wt) RSV (6). Studies in experi mental animals established 
that disease enhancement was specific to non -replicating RSV vaccines and not seen with 
infectious RSV or replicating vaccine vectors ( 7, 8).   
 
Following the failure of the formalin -inactivated RSV vaccine, attempts at developi[INVESTIGATOR_809712]-attenuated approaches ( 9). Importantly, 
throughout a period of over [ADDRESS_1119772] been evaluated in RSV-naïve infants and children, and enhanced disease following wt RSV infection of vaccinees has not been observed ( 10). Apart from the absence of enhanced disease, 
live-attenuated RSV vaccines have a number of known advantages over no n-replicating RSV 
vaccines . They can be administered intranasally, induce protective mucosal immunity in the 
respi[INVESTIGATOR_4352] (as well as systemic immunity), infect in the presence of maternally -derived RSV 
serum antibody, and have be en well tolerated and  immunogenic when administered to infants as 
young as four  weeks of age (11).  
 
Human RSV has a single serotype with two antigenic subgroups, A and B. The two subgroups 
exhibit a 3 - to 4- fold reciprocal difference in neutralization by [CONTACT_322098]. 
Analysis of glycoprotein -specific responses in infants by [CONTACT_28745]-linked immunosorbent assay 
16 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 (ELISA) with purified F and G glycoproteins showed that the fusion proteins (F proteins) were 
50% related antigenically, and the G proteins were 7% related ( 12). Consistent with this level of 
antigenic relatedness, F protein expressed by a recombinant vaccinia virus was equally protective in cotton rats against challenge with either subgroup A or B, whereas the G protein was 13- fold 
less effective against the heterologous subgroup ( 13). Thus, the F protein is responsible for most 
of the observed cross-subgroup neutralization and protection, and a subgroup A vaccine virus is likely to induce a broad immune response against wt RSV of either subgroup. Antibodies to the F 
protein are one of the endpoints evaluated in this study. 
 
The RSV vaccines to be evaluated in this study w ere derived using a recombinant 
deoxyribonucleic acid (DNA) –based technique called reverse genetics (14). The technique of 
reverse genetics has been used to produce a number of licensed vaccines; among them is 
FluMist® (MedImmune ). This technique allows de novo recovery of infectious virus entirely 
from complementary DNA (cDNA) in a qualified cell substrate under defined conditions. Reverse genetics provides a means to introduce predetermined mutations into the RSV genome 
via the cDNA intermediate. Derivation of vaccine virus from cDNA minimizes the risk of 
contamination with adventitious agents and helps to keep the passage history brief and well 
documented. Once recovered, the vaccine virus is propagated in the same manner as a biologically derived virus. As a result of repeated passage and amplification, the drug substance 
(clinical trial material [CTM] ) does not contain any recombinant DNA. The RSV  vaccin e 
candidate to be tested under this protocol is a derivative of strain A2, subgroup A.  
The drug substance RSV 6120/∆NS2/1030s is a recombinant live- attenuated RSV vaccine 
candidate that contains a deletion of the NS2 gene (ΔNS2) and a genetically stabilized version of 
the attenuating temperature sensitivity mutation at codon 1321 of the L gene termed “1030s” 
(S1313[TCA]/Y1321K[AAA]). The RSV NS2 protein functions as an interferon antagonist, and 
deletion of NS2 is attenuating ( 15-21). The 1030s mutation is also attenuating and confers a 
moderate temperature -sensitive phenotype to RSV ( 22). RSV 6120/∆NS2/1030s has  a shutoff 
temperature for replication of 40°C, and it produces only small plaques at  38°C  or above . 
Compared to recombinant wt RSV, th e RSV 6120/ ∆NS2/1030s candidate vaccine was 
significantly restricted in replication in a primary human airway epi[INVESTIGATOR_809713], and  
moderately attenuated and immunogenic in African green monkeys ( AGM ). 
 
 PRIOR RESEARCH  
 
1.2.[ADDRESS_1119773] the development of a live- attenuated RSV vaccine because of 
the advantages of live- attenuated vaccines over inactivated or subunit vaccines. These advantages 
include the ability to (i) in duce the full spectrum of protective immune responses including serum 
and local antibodies as well as CD4+ and CD8+ T cells and innate immunity ; (ii) infect and 
replicate in the presence of maternal antibody, permitting immunization of young infants; and ( iii) 
produce an acute, self-limited, attenuated infection that is well tolerated and readily eliminated from the respi[INVESTIGATOR_4352]. Another important advantage is the absence of vaccine -related  
enhanced disease, as has been confirmed in clinical studies (10). 
 Several live- attenuated RSV vaccines have been evaluated in clinical trials in adult and pediatric 
populations as part of NIAID's ongoing RSV vaccine development program ( 11, 23 -26). Four 
vaccine viruses with the NS2 deletion have been evaluated in clinical studies: rA2cpΔNS2, 
rA2cp248/404ΔNS2, rA2cp530/1009ΔNS2 ( 27), and RSV ΔNS2/Δ1313/I1314L . A brief 
summary of clinical studies involving these vaccine candidates is provided below.  
17 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 RSV Vaccine Candidates with an NS2 Deletion  
 
rA2cpΔNS2 contains the NS2 deletion as well as a set of 5 amino acid substitutions in the N, F, 
and L proteins that were identified in a cold- passaged (cp) RSV (V267I in N; E218A and T523I 
in F; and C319Y and H1690Y in L) (28, 29 ). rA2cp248/404ΔNS2 contains all of the mutations in 
rA2cpΔNS2 as well as two  additional point mutations:  "248," an amino acid substitution in the L 
protein (Q831L ) (28, 30, 31) , and "404 ," a nucleotide sub stitution in the M2 gene start signal (30, 
32). rA2cp 530/1009ΔNS2 also contains all of the mutations in rA2cpΔNS2 as well as two 
additional point mutations in L: “530” (F521L) and “1009” (M1169V) ( 33, 34).  
 rA2cpΔNS2, which had the fewest attenuating mutations, was evaluated in a dose- escalating 
study (10
5.0 PFU, 106.0 PFU, or 107.0 PFU) administered to a total of [ADDRESS_1119774], at the dose of 105.0 PFU, rA2cpΔNS2 
was shed by 3 of 8 vaccinated seropositive children with mean peak titers of 103.4 PFU/mL of 
nasal wash. Two additional children had detectable virus by [CONTACT_940] ( PCR). 
Based on these results, rA2cpΔNS2 was deemed under-attenuated, and was not further evaluated in seronegative children.  
 
rA2cp248/404ΔNS2 was evaluated in adults (n = 16 vaccinees), 15 - to 59-month-old 
RSV- seropositive children (n = 16 vaccinees), and 6- to 24-month-old RSV- seronegative children 
(n = 10 vaccinees). rA2cp248/404ΔNS2 was not shed by [CONTACT_67022]. Only one  seropositive child shed 
vaccine virus (peak titer of 10
0.4 PFU/mL of nasal wash), and four seronegative children shed 
vaccine virus (mean pea k titer of 102.3 PFU/mL of nasal wash).  
  
rA2cp530/1009ΔNS2 was also evaluated in adults (n = 19 vaccinees), 15- to 59-month -old 
RSV- seropositive children (n = 14 vaccinees), and 6 - to 24-month-old RSV- seronegative children 
(n = 15 vaccinees). rA2cp530/1009ΔNS2 was shed by [CONTACT_809778] (peak titer of 100.4 PFU/mL of 
nasal wash), none of the seropositive children, and three  seronegative children (mean peak titer of 
101.3 PFU/mL of nasal wash). In summary, deletion of the NS2 gene attenuates RSV. rA2cpΔNS2 
was over- attenuated for adults but under -attenuated for young children, whereas both 
rA2cp248/404ΔNS2 and rA2cp530/1009ΔNS2 were over- attenuated and insufficiently 
immunogenic for seronegative children ( 27). 
 
Based on these results, RSV∆NS2/∆1313/I1314L was developed. In a recent phase I trial 
([STUDY_ID_REMOVED]) , this candidate vaccine was evaluated in RSV -seropositive children 12-59 
months of  age at a dose of 106 PFU (10V, 5P), and no shedding or immune response was 
detected, indicative of attenuation. Next, it was evaluated in seronegative children 6-24 months of 
age at two sequential dose levels. At the lower dose of 105 PFU (15V, 7P), the v accine was poorly 
infectious and immunogenic:  7% of recipi[INVESTIGATOR_809714], and  53% 
developed a RSV neutralizing antibody responses. At the higher dose of 106 PFU (20V, 10P), 
80% of recipi[INVESTIGATOR_809714], and 80% developed a RSV neutralizing 
antibody response.  
 
To generate a vaccine candidate with a slightly increased level of replication compared to RSV 
ΔNS2/Δ1313/I1314L, the current candidate vaccine RSV 6120/ ∆NS2/1030s was designed. RSV 
6120/∆NS2/1030s is expected to be slightly less restricted in replication than 
RSV∆NS2/∆1313/I1314L, and more immunogenic in RSV-seronegative infants and children. 
 
18 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 1.2.2 Preclinical Studies  
[IP_ADDRESS] Temperature sensitivit y of RSV 6120/ΔNS2/1030s 
 
The shutoff temperature (T SH) was evaluated by [CONTACT_809779] 2. RSV 6120/ΔNS2/1030s is moderately temperature sensitive , with a T SH of 
40°C. The TSH is defined as the lowest restrictive temperature at which the reduction  in plaque 
number compared to that at the permissive temperature of 32ºC is 100-fold or greater than tha t 
observed for wt RSV at the 2 temperatures. Small plaques were observed at 38°C, and plaques formed at 39°C and above were characterized as micro -plaques. Temperature sensitivity results of 
the vaccine candidate RSV ∆NS2/∆1313/I1314L were included for comparison ( Table 2). As 
expected, the temperature sensitivity of RSV ∆NS2/∆1313/I1314L was slightly greater than that 
of RSV 6120/∆NS2/1030s (T
SH of 39°C, small plaque temperature [ TSP] of 37°C for RSV 
∆NS2/∆1313/I1314L; T SH of 40°C, T SP of 38°C for RSV 6120/∆NS2/1030s). 
 
Table 2: Temperature Sensitivity of Experimental Lots of RSV 6120/ΔNS2/1030s 
and RSV ΔNS2/Δ1313/I1314L 
Virus  Virus titer ( log 10 PFU per mL) at indicated temperature (°C) 
a 
Repl b 32 35 36 37 38 39 40 TSH c TSP d 
wt RSV  1 8.0 8.0 7.9 7.9 7.8 7.6 7.5 > 40 > 40   
wt RSV  2 6.7 6.9 6.8 6.8 6.9 6.8 6.6 > 40 > 40   
RSV ∆NS2 ∆1313 I1314L 1 7.5 7.3 7.0 6.7 5.7 1.7 < 1 39 37 
RSV 6120/ ∆NS2/1030s 2 7.8 7.9 7.9 7.7 7.8 7.5e 5.5e 40 38 
 
a   The temperature sensitivity ( ts) phenotype for each virus was evaluated by [CONTACT_809780]. For viruses with ts phenotype, titers at shutoff temperatures are marked (bold, underlined). 
Vero cells were used for the ∆NS2 viruses because loss of expr ession of NS2 renders RSV more sensitive to type I 
interferon, which is not made by [CONTACT_809781]. See footnote c for the definition of shutoff temperature.  
b wt RSV rows 1 and 2 represent duplicate dilution series of the same virus that were examined in para llel in the same 
experiment. Differences between these replicas illustrate the variability that is inherent in these biological experiments.  
c Shutoff temperature (T SH, bold, underlined) is defined as the lowest restrictive temperature at which the reduct ion 
compared to 32ºC is 100-fold or greater than that observed for wt RSV at the two temperatures. The ts phenotype is 
defined as having a shutoff temperature of 40ºC or less.  
d TSP, small plaque temperature , is defined as the lowest restrictive temperatur e at which the small -plaque phenotype 
is observed.  
e At 39 and 40°C, RSV 6120/ ∆NS2/1030s formed micro-plaques.  
[IP_ADDRESS] Replication of an e xperimental lot of RSV 6120/ΔNS2/1030s in an in -vitro model of 
mucociliary  normal human tracheal/bronchial  epi[INVESTIGATOR_809715] 6120/ΔNS2/1030s was evaluated in a 3D 
mucociliary  human tissue model consisting of normal differentiated primary human 
tracheal/bronchial airway epi[INVESTIGATOR_1663] (Epi[INVESTIGATOR_385605], Mattek, Inc.). Virus replication was evaluated at two different temperatures (32°C and 37°C) to model the temperatures of the upper 
and lower airways. Pseudostratified differentiated airway cells were cultured in an air-liquid 
interface in 12 -mm transwell inserts with 0.4 µM pore sizes in Dulbecco’s Modified Eagle 
Medium (D MEM ), supplemented with a proprietary mix of epi[INVESTIGATOR_809716]. Prior to infection, the api[INVESTIGATOR_809717] 500 µL 
19 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 PBS to remove any accumulated mucus. Triplicate wells were infected at a multiplicity of 
infection of 0.1 with 100 µl per well of RSV 6120/ΔNS2/1030s. To evaluate replication at 32°C, 
recombinant wt RSV A2 and RSV ΔNS2/Δ1313/I1314L were included for comparison. At 37°C, 
only recombinant wt RSV was included for comparison. After [ADDRESS_1119775]-infection to assay viral 
replication, then snap-frozen, and virus titers were determined by [CONTACT_809782].  
 
Recomb inant wt RSV of strain A2 replicated efficiently in differentiated primary human 
tracheal/bronchial epi[INVESTIGATOR_809718] 32°C and at 37°C ( Figure 3). At 32°C, peak titers of wt RSV 
were detectable on day 6, whereas at 37°C, peak titers were reached by [CONTACT_4475] [ADDRESS_1119776]-infection. The temperature -sensitive virus RSV ΔNS2/Δ1313/I1314L, which differs from RSV 
6120/ΔNS2/1030s only by [CONTACT_809783] L ORF, was included for comparison at the lower temperature, 32°C. Peak titer s of this virus were about 200 -fold lower than those of wt  
RSV at 32°C. RSV 6120/ΔNS2/1030s replicated to slightly higher titers than RSV ΔNS2/∆1313/I1314L, showing that indeed, RSV ΔNS2 with the 1030s mutation is slightly less 
restricted for replication than RSV ΔNS2 with  the genetically stabilized deletion of codon 1313 
of the L ORF. At 37°C, the difference in peak titers between RSV 6120/ΔNS2/1030s and wt RSV was statistically significant.   
 
Figure 3: Multicycle Replication of E xperimental Lots in an in-vitro Model of 
Normal H uman Bronchial/ Tracheal Epi[INVESTIGATOR_809719] a multiplicity of infection of 0.1, and supernatants were harvested daily for 7 days, snap- frozen, and titered later on Vero  cells. A: replication at 32°C. B: replication at 37°C.  
  

20 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 [IP_ADDRESS] Replication of experimental lot and CTM  of RSV 6120/ΔNS2 /1030s in African 
green monkeys (AGMs ) 
 
Replication and immunogenicity of RSV 6120/ΔNS2/1030s were evaluated in nonhuman 
primates  (NHPs), specifically  African green monkeys (AGM). AGMs  are semi -permissive for 
RSV. The first NHP study was done in AGMs to evaluate an e xperimental lot of RSV 
6120/ΔNS2/1030s, and a second study was done to evaluate the CTM (Lot RSV#012A). AGMs 
that were  seronegative for RSV were inoculated intranasally  (i.n.) and intratracheally  (i.t.)  with 
RSV 6120/ΔNS2/1030s; a dose of 1 x 106 PFU of vaccine in a 1- mL volume per site was 
administered to sedated juvenile male and female AGMs (total dose per animal: 2 x 106 PFU). 
Nasopharyngeal swabs were collected daily on days 0 through 10 and on days 12 and 14; tracheal 
lavage (TL) samples were collected every other day from days 2 through 14; and virus shedding 
was analyzed by [CONTACT_809784]. Serum RSV  neutralizing antibody titers were determined 
by a complement -enhanced 60% plaque reduction neutralization assay. Results from studies 
following the same protocol, performed in animals from the same group and origin, inoculated with recombinant wtRSV A2 at the same dose, were included for comparison. Studies were 
approved by [CONTACT_809785], NIH.   
 In both studies, s hedding of the RSV 6120/ΔNS2/1030s viru s from the upper respi[INVESTIGATOR_4352] 
(URT) and lower respi[INVESTIGATOR_4352] (LRT)  was detectable over several days. In both studies, t he 
mean peak tite rs of RSV 6120/ΔNS2/1030s in the nasopharyngeal samples  was 3.8 log
10 PFU per 
mL. These mean peak titer s were slightly  lower than that of wt RSV A2 (4.2 log 10 PFU per mL),  
but higher than t hose of the previously tested RSV ΔNS2/Δ1313/I1314L virus (3.2 log 10 PFU per 
mL). The mean peak titers in the  LRT, detectable in TL samples,  were 4.6 log 10 PFU per mL for 
the Experimental Lot of RSV 6120/ΔNS2/1030s, and 2.9 PFU per mL for the CTM of RSV 
6120/ΔNS2/1030s. Shedding was observed in all AGMs in both URT and LRT. Compared to the RSV ΔNS2 /Δ1313/ I1314L virus, which showed much lower mean peak titers (1.4  log
10 PFU per 
mL) with only a 75% infection rate (virus replication detected in 3 out of 4 animals), the study virus RSV 6120/ΔNS2/1030s was less attenuated in the AGMs (Appendix I , Table 27, Table 28).  
 
In both studies, the RSV 6120/ΔNS2/1030s virus induced serum neutralizing antibodies . In the 
first study of the experimental lot, the neutralizing antibody titers were  comparable to or slightl y 
higher than wt RSV A2 and the previously tested RSV vaccine virus (RSV ΔNS2 /Δ1313/I1314L) 
(Appendix I , Table 29). The CTM induced titers that were slighly lower than those of wt RSV, 
and comparable to those of RSV ΔNS2 /Δ1313/I1314L. These results show that at a total dose of 
2 x 10
6 PFU, administered i.n. a nd i.t., RSV 6120/ΔNS2/1030s is immunogenic in AGMs. 
 
1.2.3 Previous Clinical Experience  
 
The live- attenuated recombinant RSV 6120/∆NS2/1030s vaccine virus is being evaluated for 
the first time in humans. Based on preclinical data, RSV 6120/∆NS2/1030s is expected to be more attenuated than the previously tested vaccine candidate rA2cpΔNS2, but less attenuated 
than the vaccine candidates rA2cp248/404ΔNS2 and rA2cp530/1009ΔNS2, which were 
deemed over- attenuat ed in seronegative infants and children , and slightly less attenuated and 
more immunogenic than RSV∆NS2/∆1313/I1314L. As noted above, this vaccine is predicted to be attenuated and well tolerated  in seropositive and seronegative children. 
 
  
21 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 
 RATIONALE  
 
 CLINICAL DEVELOPMENT PLAN 
 
The investigational RSV vaccine RSV 6120/ΔNS2/1030s will be evaluated sequentially in 
RSV-seropositive children followed by [CONTACT_809786]- seronegative infants and children. The 
main purpose of this study is to determine whether RSV 6120/ΔNS2/1030s is well tolerated and restricted in replication in RSV -seropositive children, and well tolerated , infectious, 
immun ogenic, and genetically stable in RSV- seronegative infants and children. If the study 
product is found to be well tolerated , infectious, and immunogenic in RSV- seronegative infants 
and children , then a safety and immunogenicity study in infants < 6 months of age will be  
initiated . Plans will be made in consultation with industry collaborators as a lead RSV vaccine 
candidate is identified.  
 
The primary immunogenicity endpoints to be evaluated are RSV neutralizing antibody titer, and 
RSV F protein antibody (by [CONTACT_6428]). Neutralizing antibody is a well- established and important 
surrogate marker of effective immunity to RSV disease. Antibodies to the F protein are also 
associated with cross-subgroup neutralization and protection ( 13). These assays will be performed 
at the Johns Hopkins University ( JHU) CIR laboratory. 
 
 HYPOTHESES  
 
RSV 6120/∆NS2/1030s will be well-tolerated in  RSV- seroposit ive and RSV-naï ve participants. 
In RSV -seronegative participants, RSV 6120/ΔNS2/1030s is expected to be safe and result in 
infection, limited vaccine replication, and the induction of a neutralizing antibody response to 
RSV.   
 
 OBJECTIVES  
 
2.1. PRIMARY OBJECTIVES  
 
Safety 
1. To assess the frequency and severity of study product–related solicited and unsolicited AEs in 
RSV- seropositive participants (group 1) from day [ADDRESS_1119777]–related solicited and unsolicited AEs in 
RSV- seronegative participants ( group 2) from day [ADDRESS_1119778]–related serious adverse events (SAEs) in RSV -seropositive participants 
(group 1) from day [ADDRESS_1119779]–related SAEs in RSV -seronegative participants ( group 2) from day 0 
through the 56th day following inoc ulation   
  
Infectivity  
1. To determine the peak titer of vaccine virus shed and duration of virus shedding by [CONTACT_20908]  
2. To assess the proportion of vaccinated participants infected with study vaccine ( If < 70% of 
RSV-seronegative vaccine es are infect ed with vaccine virus, the study product will be considered 
over- attenuated. ) 
 
Immunogenicity 
1. To characterize serum antibody responses to the study product 28 days after inoculation of RSV -
seropositive vaccine recipi[INVESTIGATOR_840] (group 1)  
22 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119780] 56 days after inoculation of RSV-
seronegative vaccine recipi[INVESTIGATOR_840] ( group 2 )   
2.2. SECONDARY OBJECTIVES  
 
1. To characterize the freque ncy and severity of symptomatic medically attended respi[INVESTIGATOR_809720] -seronegative vaccine and placebo recipi[INVESTIGATOR_840] (group 2) who experience 
natural infection with wt RSV during the sub sequent RSV season(s)  
2. To characterize serum antibody responses in RSV- seronegative vaccine and placebo recipi[INVESTIGATOR_840] 
(group 2) who experience natural infection with wt RSV during the subsequent RSV season(s)  
3. To characterize mucosal antibody responses to vacc ine in RSV-seropositive (group 1) and RSV-
seronegative (group 2 ) participants  
 
2.3. EXPLORATORY OBJECTIVE  
 
Study samples may be used in comp arative assays with  samples from other RSV vaccine studies 
initiated by [CONTACT_322114] , NIAID, NIH. 
 
 STUDY DESIGN  
 
The study will be double-blind, randomized, and placebo-controlled. Participants in groups 1 and 
2 will be block -randomized in groups of 3 at a ratio of 2:1 to receive vaccine or placebo, 
respectively . The vaccine will be evaluated in a stepwise fashion beginning with 
RSV- seropositive children (Group 1)  and proceeding sequentially in RSV-seronegative children 
(Group 2).  For the purpose of this study, RSV-seropos itive is defined as having a serum 
neutralizing antibody titer of ≥ 1:40 , and RSV- seronegative is defined as having a serum 
neutralizing antibody titer of < 1:40. This definition has been used in previous evaluations of live-
attenuated RSV vaccines (11, 24, 35 ). In these previous studies, live- attenuated RSV vaccines 
were highly restricted in replication and poorly immunogenic in children with titers ≥ 1:40 but 
were far less restricted in replication and highly immunogenic in children with titers < 1:40. 
These data suggest that this neutralizing antibody cutoff can distinguish effectively between 
RSV- experienced and RSV -naïve children. 
 The study w ill proceed to g roup [ADDRESS_1119781] respi[INVESTIGATOR_809708] > [ADDRESS_1119782], Day  0, and will occur between 
April 1 and October 31 to avoid the time during which wt RSV typi[INVESTIGATOR_809721] ( Appendix V , Figure 6) . Accrual will stop prior to November 1. 
  For group 1, RSV-seropositive participants, the duration of participation in the initial phase  of the 
study is [ADDRESS_1119783] -Acute Phase from the 29th day through the 56th 
day after inoculation.  
 
23 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 During t he Acute Phase, the participants’  parent s/guardians will be contact[CONTACT_809787] y. These 
contacts will consist either of  an in-person evaluation of interim medical history, clinical 
assessment, and nasal rinse , or an  interim medical history conducted by a mutually agreed upon 
communication method. During the Acute Phase,  the participants will be evaluated for AEs  or 
SAEs. Participant s who have a febrile or respi[INVESTIGATOR_809722] a study visit 
to perform a nasal rinse. The nasal rinse will  be tested for RSV and for other respi[INVESTIGATOR_13521] y 
pathogens that are considered adventitious agents. During the Post-A cute Phase,  study 
participants ’ parents/guardians will be instructed to contact [CONTACT_809788] . The 
RSV- seropositive participants will have a scheduled follow -up visit on the 28th day after 
inoculation , and the RSV -seronegative participants will have a scheduled follow -up visit on the 
56th day after inoculation. The schedules of evaluations during the Acute Phase and Post-A cute 
Phase are shown in Appendix II , Table 30. 
 
For the RSV -seronegative participants (group 2), t he study has a third phase that assesses the 
incidence and severity of illness suggestive of RSV occurring during the RSV season following inoculation. During the RSV Season Surveillance Period, encompassing November [ADDRESS_1119784] with the participant s’ parent s/guardians to identify 
medically attended epi[INVESTIGATOR_809723], URI , LRI, or otitis media. P articipant s who have such an 
epi[INVESTIGATOR_322029]- person evaluation of interim medical history, clinical assessment, and 
nasal rinse  to evaluate for RSV and other respi[INVESTIGATOR_809724] (Appendix III ).  
 The RSV -seronegative participants will also have a study visit during the pre -RSV season  
between October [ADDRESS_1119785] a blood sample and nasal rinse  sample  and/or nasosorption 
synth etic absorptive matrix ( SAM ) strip for immunological assays . The sample s will be used to 
assess the durability of the vaccine respons e. Participants will have a post -RSV season visit to 
collect blood and nasal rinse  and/or nasosorption SAM strip specimens to further assess the 
durability of the vaccine response and to assess the immune response to naturally occurring wt RSV infection.. The RSV -seronegative participants may have an  overlap between the initial 
phases and the RSV surveillance phase of the study, depending upon the date of inoculation.  
 
 STUDY POPULATION 
 Approximately 15 RSV-seropositive children ≥ 12 months to < 60 months of age will be enrolled; 
10 will receive a single dose of 10
5.7 PFU of vaccine and 5 will receive a single dose of placebo. 
Subsequently, 21 to 30 RSV -seronegative infants and children ≥ 6 months to < 25 months of age  
will be enrolled in the study and will receive a single dose of either 105.0 PFU of vaccine or 
placeb o in a 2:1 ratio. These numbers were chosen based upon experience with phase I evaluation 
of other live -attenuated respi[INVESTIGATOR_322031] ( 11,23,25 ) and statistical 
considerations ( Section  9).  
 
Placebo recipi[INVESTIGATOR_809725]. These 
numbers were chosen based upon experience with p hase I eva luation of other live- attenuated 
respi[INVESTIGATOR_322031] (11,23,25 ) and statistical considerations ( Section  9). 
 
Infants and children will be selected for participation according to the described study- specific 
co-enrollment considerations; the recruitment, screening, and enrollment process; and participant 
retention and withdrawal or termination.  
24 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119786] meet all of the following inc lusion c riteria to be 
enrolled in this study:  
 
4.1.1.  ≥ 12 months of age and <  60 months of age at the time of inoculation  
4.1.2.  Screening serum specimen for RSV-neutralizing antibody is obtained within the calendar 
year of inoculation  
4.1.3.  Seropositive for RSV antibody, defined as serum RSV-neutralizing antibody titer ≥ 1:[ADDRESS_1119787], history, and physical examination  at 
the time of inoculation  
4.1.6.  Received routine immunizations appropriate for age based on the Advisory Committee on 
Immunization Practices (ACIP) Recommended Immunization Schedule for Children and 
Adolescents Aged [ADDRESS_1119788] percentile for age  
4.1.8.  Expected to be available for the duration of the study 
4.1.9.  Parent/guardi an is willing and able to provide written informed consent  
 
 EXCLUSION CRITERIA FOR RSV-S EROPOSITIVE CHILDREN  
 
Potential RSV -seropositive participants who meet any of the following exclusion cri teria will be 
excluded from participation in this study: 
 
4.2.1.  Born at less than [ADDRESS_1119789]  
4.2.3.  Evidence of chronic disease 
4.2.4.  Known or suspected impairment of immune function  
4.2.5.  Bone marrow/solid organ transplant recipi[INVESTIGATOR_841]  
4.2.6.  Major congenital malformations, including congenital cleft palate or cytogenetic abnormalities  
4.2.7.  Suspected or documented developmental disorder, delay, or other developmental problem  
4.2.8.  Cardiac abnormality requiring treatment  
4.2.9.  Lung disease or reactive airway disease  
4.2.10.  More than one epi[INVESTIGATOR_809726]  
4.2.11.  Wheezing epi[INVESTIGATOR_322047] 12 months  
4.2.12.  Wheezing epi[INVESTIGATOR_809727] 12 months  
4.2.13.  Previous receipt of supplemental oxygen therapy in a home setting  
25 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119790] 6 months  
4.2.18.  Previous anaphylactic reaction  
4.2.19.  Previous vaccine- associated adverse reaction that was Grade 3 or above  
4.2.20.  Known hypersensitivity to any vaccine component  
4.2.21.  Member of a h ousehold that contains an infant who is less than 1 2 months of age at the 
date of inoculation through the 10th day after inoculation  
4.2.22.  Member of a household that, at  the date of inoculation through the 10th day after 
inoculation , contains an immunocompromis ed individual including but not limited to:  
• a person who is HIV- infected  
• a person who has received chemotherapy within the 12 months prior to enrollment 
• a person receiving immunosuppressant agents  
• a person living with a solid organ or bone marrow transplan t 
4.2.23.  Will attend a daycare facility that does not separate children by [CONTACT_809789] < 12 months of age at the date of inoculation through the 10th day after inoculation  
4.2.24.  Receipt of any of the following prior to enrollment:  
• any inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days prior, or  
• any live vaccine, other than rotavirus vaccine, within the 28 days prior, or 
• another investigational vaccine or investigational drug within 28 days prior, or 
• salicylate (aspi[INVESTIGATOR_248]) or salicylate-containing products within the past 28 days 
4.2.25.  Scheduled administration of any of the following after planned inoculation:  
• inactivated vaccine or live- attenuated rotavirus vaccine within the 14 days after, or  
• any live vaccine other than rotavirus in the 28 days after, or  
• another investigational vaccine or investigational drug in the 28 days after  
4.2.26.  Receipt of any of the following medications within 3 days of study enrollment:  
• systemic antibacterial, antiviral, antifungal, anti -parasitic, or antituberculous agents, 
whether for treatment or prophylaxis, or 
• intranasal medications, or 
• other prescription medications except the permitted concomitant medications listed 
below 
Permitted  concomitant medications (prescription or non -prescription) include nutritional 
supplements, medications for gastroesophageal reflux, eye drops, and topi[INVESTIGATOR_5910], including (but not limited to) cutaneous (topi[INVESTIGATOR_2855]) steroids, topi[INVESTIGATOR_8163], and topi[INVESTIGATOR_809728].  
4.2.27.  Any of the following events at the time of enrollment:  
• fever (temporal or rectal temperature of ≥100.4°F), or  
• upper respi[INVESTIGATOR_145283] (rhinorrhea, cough, or pharyngitis) or 
• nasal congestion significant enough to interfere with successful inoculation, or  
• otitis media  
26 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
  
 INCLUSION CRITERIA FOR RSV-S ERONEGATIVE INFANTS & CHILDREN  
 
Potential RSV -seronegative participants must meet  all of the following inclusion criteria to be 
enrolled in  this study:  
 
4.3.1.  ≥ 6 months  of age and <  25 months of age  at the  time of inoculation  
4.3.2.  Screening and pre-inoculation serum specimen s for RSV -neutralizing antibody are 
obtained no more than 42 days prior to inoculation  
4.3.3.  Seronegative for RSV antibody, defined as serum RSV -neutralizing antibody titer <  1:[ADDRESS_1119791] growth chart, AND 
• If < 1 year of age: has a current height and weight above the 5th percentile for age   
• If ≥ 1 year of age: has a current height and weight above the 3rd percentile for age  
4.3.7.  Expected to be available for the duration of the study  
4.3.8.  Parent/guardian is willing and able to provide written informed consent   
 
 EXCLUSION CRITERIA FOR RSV-S ERONEGATIVE INFANTS & CHILDREN  
 
Potential RSV -seronegative participants who meet any of the following criteria will be excluded 
from this study: 
 
4.4.1.  Born at less than [ADDRESS_1119792]  
4.4.4.  Evidence of chronic disease 
4.4.5.  Known  or suspected infection or impairment of immunological functions  
4.4.6.  Bone marrow/solid organ transplant recipi[INVESTIGATOR_841]  
4.4.7.  Major  congenital malformations , including c ongenital cleft palate or cytogenetic 
abnormalities  
4.4.8.  Suspected or documented developmental disorder, delay, or other developmental problem  
4.4.9.  Cardiac abnormality requiring treatment  
4.4.10.  Lung disease or reactive airway disease  
4.4.11.  More than one epi[INVESTIGATOR_809726]  
4.4.12.  Whee zing epi[INVESTIGATOR_322047] 12 months  
4.4.13.  Wheezing epi[INVESTIGATOR_809727] 12 months  
4.4.14.  Previous receipt of supplemental oxygen therapy in a home setting  
27 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119793] component  
4.4.22.  Member  of a household that contains an infant who is less than 6 months of age at the date 
of inoculation through the 28th day after inoculation  
4.4.23.  Member  of a household that, at the date of inoculation through the 28th day after 
inoculation,  contains an immunocompromised individual  including but not limited to:  
• a person who is HIV- infected  
• a person who has cancer and has received chemotherapy within the 12 months prior to 
enrollment  
• a person living with a solid organ or bone marrow transplant  
4.4.24.  Attends a daycare facility that does not separate children by [CONTACT_322135] < 6 
months of age at the date of inoculation through the 28th day after inoculation  
4.4.25.  Receipt  of any of the following prior to enrollment:  
• any inactivated vaccine or liv e-attenuated rotavirus vaccine within the 14 days prior, or  
• any live vaccine, other than rotavirus vaccine, within the 28 days prior, or 
• another investigational vaccine or investigational drug within 28 days prior, or 
• salicylate (aspi[INVESTIGATOR_248]) or salicylate- containing products within the past 28 days 
4.4.26.  Scheduled administration of  any of the following after planned inoculation  
• inactivated vaccine or live- attenuated rotavirus vaccine within the 14 days after, or 
• any live vaccine other than rotavirus in the 28 days after, or 
• another investigational vaccine or investigational drug in the 56 days after  
4.4.27.  Receipt of any of the following medications within 3 days of study enrollment:  
• systemic antibacterial, antiviral, antifungal, anti -parasitic, or antituberculous agents, 
whether for treatment or prophylaxis, or 
• intranasal medications, or 
• other prescription medications except the permitted concomitant medications listed 
below 
Permitted concomitant medications (prescription or non -prescription) include nutritional 
supplements, medications for gastroesophageal reflux, eye drops, and topi[INVESTIGATOR_5910], 
including (but not limited to) cutaneous (topi[INVESTIGATOR_2855]) steroids, topi[INVESTIGATOR_8163], and topi[INVESTIGATOR_809728].  
4.4.28.  Any of the following events at the time of enrollment:  
• fever (t emporal or rectal temperature of ≥100.4°F), or  
• upper respi[INVESTIGATOR_145283] (rhinorrhea, cough, or pharyngitis) or 
• nasal congestion significant enough to interfere with successful inoculation, or  
• otitis media  
28 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119794] completed the initial RSV season surveillance 
portion of the study and whose parent/guardian is willing and able to provide written 
informed consent  
4.5.2.  Expected to be available during the second year of RSV surveillance  
 
 EXCLUSION CRITERIA FOR RSV-S ERONEGATIVE CHILDREN PARTICIPATING IN A 
SECOND SEASON  OF RSV  SURVEILLANCE   
 
4.6.1.   Currently enrolled in another RSV study  
 
 CO-ENROLLMENT CONSIDERATIONS  
 
Co-enrollment to an investigational vaccine or investigational drug study is not allowed during 
the Acute Phase or Post -Acute Phase of th is study. After the Post- Acute Phase, co -enrollment 
may be considered at the discretion of the principal investigator ( PI). 
 
 RE-ENROLLMENT CONSIDERATIONS  
 Participants who receive placebo may re-enroll in the initial study following completion of the initial  RSV surveillance period if they continue to meet all eligibility requirements.  
 
 RECRUITMENT PROCESS  
 
CIR research staff will recruit participants from p ediatric practices and clinics in the greater 
Baltimore/Washington area. Upon referral by [CONTACT_3038]’  primary care provider or the 
provider’s staff, CIR staff will approach parents/guardians, present  them with  IRB -approved 
informational brochures, and obtain contact [CONTACT_3031]. Study staff will contact [CONTACT_809790]/guardians to elaborate upon the details and requirements of the study.    CIR research staff may  also recruit participants through mailing IRB -approved documents to 
children of local  pediatric practices and clinics, and to households i n local zip codes containing age -
appropriate children . In addition, CIR staff may recruit participants through group gatherings such 
as health fairs and by [CONTACT_643333]-approved recruitment  materials.   
 If parents/guardians are interested in having their child participate and the child meets the minimum 
inclusion and exclusion criteria, then the study staff will schedule a screen ing visit to determine  the 
child’s eligibility.   
 
After the first year of RSV surveillance is completed, the p arents/guardians of children enrolled in 
group [ADDRESS_1119795] their child ren participate in a second year of RSV surveillance.  
Participation is optional, and separate consent will be obtained for participation in this portion of 
the study. 
 
29 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119796] will be encouraged to remain in the safety evaluation for the duration of the study even if sample collection is refused.  
 
A participant  may withdraw or terminate participation in the study early for any of the following 
reasons:  
• Withdrawal of consent – applies to a parent/guardian who verbally or in writing withdraws 
consent for the participant to continue in the study for any reason. 
• Noncompliant with protocol – applies to a parent/guardian who does not comply with 
protocol- specific visits or eva luations on a consistent basis, such that adequate follow-up is 
not possible and the p articipant ’s safety would be compromised  by [CONTACT_116680].  
• Investigator discretion – p articipant  withdrawal may occur if the investigator believes that it 
is in the best interest of the participant . 
• Other – a category used when previous categories do not apply; requires an explanation.  
 
The study may be ended for the following reasons: 
• Research is terminated by [CONTACT_322129] – applies to the situation where the entire 
study is terminated by [CONTACT_974]. 
• The study s ponsor , CIR,  the institutional review board ( IRB), the Office for Human Research 
Protections (OHRP), NIAID, or the US Food and Drug Administration ( FDA) may decide to 
end the study. 
 
For any participant who withdraws or who is terminated from the study prior to completion of follow-up, study staff will document the reason for the withdrawal or termination. In the event 
that the circumstances that led to a participant’s withdrawal or termination change, the study staff 
will con tact the PI [INVESTIGATOR_809729]-up.  Withdrawn subjects will not 
be replaced.  
Participants  enrolled  in the optional  second year of RSV season surveillance may voluntarily 
withdraw before the conclusion of the second year RSV  surveillance season.  
 
 STUDY PRODUCT  
 
The unblinded dispenser should consult standard operating procedures (SOPs) and the study manual of operations (MOP). Refer to  Figure 1 for an overview of the study design and to the 
investigator’s brochure (IB) for further information about the study product. 
 
• Group 1 : Live Recombinant Respi[INVESTIGATOR_809730] V 6120/∆NS2/1030s, approximately 
10
5.7 PFU per 1.0 mL vaccine 
• Group 2: Live Recombinant Respi[INVESTIGATOR_809731] 6120/∆NS2/1030s, approximately 
105.0 PFU per 0.5 mL vaccine 
• Group 1: Placebo for the RSV vaccine will be Lactated Ringer’s Solution for Injection, USP 1.0 
mL 
30 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 • Group 2: Placebo for the RSV vaccine will be Lactated Ringer’s Solution for Injection, USP 0.[ADDRESS_1119797]  REGIMEN S 
 
Enrolled study participants will receive a single dose of RSV 6120/∆NS2/1030s vaccine or 
placebo, administered as nose drops.  
 
 STUDY PRODUCT  FORMULATION  
 
5.2.1 RSV 6120/∆NS2/1030s  
 
The RSV 6120/∆NS2/1030s vaccine is provided in a sterile 2.0-mL cryovial, each containing 0.6 
mL of vaccine (Lot RSV #012A). The vaccine virus concentrate is diluted by [CONTACT_809791] a dose of approximately 105.7 PFU (group 1) in 1.0 mL  or 105.0 PFU (group 2) in  a 
0.5-mL volume. The vaccine vial is labeled as shown in Figure 4.  
 
Figure 4: Investigational Product Label Sample  
Live recombinant Respi[INVESTIGATOR_809732] 6120/ΔNS2/1030s  
VERO GROWN VIRUS VACCINE  
Date: 29AUG2016  
Vial#:XXXX 
Lot: RSV#012A  
CAUTION:NEW DRUG LIMITED  
 BY [CONTACT_949] ([LOCATION_003]) LAW  
TO INVESTIGATIONAL USE  
Store at –80°C ± 15°C 
Charles River Laboratories, Malvern, PA  
(Enlarged Sample)  
 
5.2.2 Diluent for RSV 6120/∆NS2/1030s  
 
The diluent for RSV 6120/∆NS2/1030s is Lactated Ringer’s Solution for Injection, USP.  
 
5.2.3 Placebo for RSV 6120/∆NS2/1030s   
 
The placebo for RSV 6120/∆NS2/1030s is Lactated Ringer’s Solution for Injection, USP. 
 
 
 STUDY PRODUCT  STORAGE  
 
Vaccine will be stored in a secure freezer  at -80°C ± 15°C. It must remain frozen until the time of 
use. Once the vaccine is thawed, it should never be refrozen for reuse. Vaccine will be prepared 
from new, unopened containers for each use.  
 
31 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 Lactated Ringer’s Solution for Injection, USP should be stored at room temperature as 
recommended by [CONTACT_322137]. Vaccine 
diluent/placebo must be transferred to a secure 2°C to 8°C refrigerator at least 24 hours  before 
use.   
Procedures for managing the vaccine and diluent/placebo shipment are in the MOP. 
 
 STUDY PRODUCT PREPARATION  
 
The diluent for the vaccine, the placebo for the vaccine , and the RSV vaccine must be prepared 
by [CONTACT_809792].  
 The unblinded dispenser will prepare the correct dose of study product for each participant in a 
biological s afety cabinet (BSC) or compounding a septic containment i solator (CACI) using 
aseptic technique. If necessary to preserve blinding, all prepared syringes will be as described in 
the MOP.  
  
5.4.1 Diluent  
 
The diluent is Lactated Ringe r’s Solution for Injection, USP. 
 
 
5.4.2 Placebo  
 
Placebo is Lactated Ringer’s Solution for Injection, USP.  
 Placebo will be drawn up in a sterile syringe  to a volume of 1.0 mL for group 1 and to a volume 
of 0.5 mL for group 2 and labeled per instructions in the MOP. If necessary  to preserve blinding, 
all prepared syringes will be as described in the MOP.  
 
5.4.3 Live RSV 6120/∆NS2/1030s  
 Diluent will be prepared prior to removal of vaccine from the freezer. The MOP will be followed 
for proper handling of the study product.   
Approximat ely three vials per dose of undiluted vaccine will be  used to prepare the 
administration dose . When manipulating the undiluted study product, the  smallest  gauge needle 
possible will be used to avoid loss of study product in the needle and syringe hub. Conc entration 
of the undiluted study product is approximately [ADDRESS_1119798] will 
be thawed and diluted with Lactated Ringer’s Solution for Injection, USP to a dose of 
approximately 105.[ADDRESS_1119799] will be thawed and diluted with Lactated Ringer’s Solution for Injection, 
USP to a dose of approximately  105.[ADDRESS_1119800] w ill be drawn up to a volume of 1.0 mL (group 1) or  0.5 mL (group 2) 
in a sterile syringe and labeled per instructions in the MOP. The labeled  filled syringes will be 
transported in a cooler at 2ºC to 8ºC with ice or cold packs to the clinical site for admi nistration. 
Vaccine must be administered within [ADDRESS_1119801] 
be administered within 4 hours of being removed from the refrigerator. 
 
32 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 Samples of undiluted (if available) and diluted study product will be aliquoted from the remaining 
vaccine that has been prepared. The samples will be snap -frozen as per the MOP and stored at  
-80°C ± 15°C separate from the concentrated study product. Titration of vaccine will be  
completed to confirm the titer of the vaccine administered to the participants.  
 The MOP provides detailed instructions on vaccine storage, handling, preparation, labeling and 
transport to the clinic.  
 
 STUDY PRODUCT INOCULATION PROCEDURE  
 
All study participants will receive a single dose of study product, administered as nose drops. There is no nasal preparation prior to administration. While the participant is supi[INVESTIGATOR_050], a volume of 1.0 mL (group 1) or 0.5 mL (group 2) of study product will be delivered as nose drops 
(approximately 0.5 mL [group 1] or 0.25 mL [group 2] per nostril) using a sterile, needle- less, 
masked syringe. Participant will remain supi[INVESTIGATOR_17044] [ADDRESS_1119802] ACQUISITION  
 
The c linical lot of RSV 6120/∆NS2/1030s w as generated  by [CONTACT_722259] (CRL) 
using t he seed virus provided by t he NI H.  
 Lactated Ringer’s Solution for Injection, USP will be used  as diluent and p lacebo . 
 
Vaccine virus will be stored at  a NIAID -designated commercial repository until formally 
requested by [CONTACT_978]/designee. Prior to IRB  approval and FDA safe to proceed  determination , the 
PI/designee at JHU CIR may request that vials of vaccine be transferred  from the sponsor to the 
CIR laboratories at the JHSPH for confirmation of the vaccine titer . However, only a fter receipt  
of IRB appr oval and FDA safe to proceed  determination , will  vials of vaccine be used for 
administration to study subjects . Such an initial shipment may contain the full number of vials 
needed for implementation of the protocol, but no vaccine will be administered to participants 
until all necessary approvals have been received. Procedures for ordering and shippi[INVESTIGATOR_809733].   
 STUDY  PRODUCT  ACCOUNTABILITY  
 The unblinded dispenser  is responsible for maintaining an accurate inventory and accountability 
record of study-product and Lactated Ringer’s Solution for Injection, USP for this study.
 A copy 
of the randomization code will be retained by [CONTACT_809793] e MOP. 
Without written request to unblind, the randomization code may not be released. The unblinded 
dispenser will be respo nsible for maintaining the blind.  
  
33 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 
 DISPOSITION OF USED/UNUSED STUDY PRODUCT  
 
After the unblinded dispenser dilutes the vaccine and  draws up the vaccine into a syringe for 
administration, the label will be removed from the vaccine vials used for preparation and placed 
in the accountability log. In this manner, monitoring personnel will be able to verify the 
accountability of all vaccine vials used for the study. If there is any vaccine left after the syringes 
have been drawn up and aliquots have been removed for titering, it will be destroyed by [CONTACT_809794].  
 
 FINAL DISPOSITION OF STUDY PRODUCTS  
 
After study completion or termination, all unused study product will be disposed of per the 
sponsor’s instructions.  
  
 CONCOMITANT MEDICATIONS  
 Permitted concomitant medications at enrollment (prescription or non -prescription) include 
nutritional supplements, medications for gastroesophageal reflux, eye drops, and topi[INVESTIGATOR_146934], including (but not limited to) cutaneous (topi[INVESTIGATOR_2855]) steroids, topi[INVESTIGATOR_8163], and topi[INVESTIGATOR_296114]. 
 
The use of prophylactic antipyretics, decongestants, or antihistamines is discouraged during the 
Acute Phase : day of inoculation day through the 10
th day after inoculation for group 1; and day of 
inoculation  through the 28th day following inoculation for group 2. H owever, use of these 
medicati ons for treatment of symptoms is allowed.  
 Due to the potentially confounding effect on study immunogenicity results, the following concomitant medications should be avoided after inoculation  unless deemed clinically necessary.  
 
• Licensed inactivated vacc ine or live -attenuated  rotavirus vaccine within 14 days of 
inoculation  
• Licensed live virus vaccine, other than rotaviru s vaccine, within 28 days of inoculation 
• Systemic corticosteroids for more than 14 days at a dosage equivalent to prednisone at 
> 2 mg/kg or 20 mg daily, or other immune -modifying drugs within 28 days of inoculation 
• Immunoglobulins and/or any blood products within 28 days of inoculation 
• Investigat ional drug or investigational vaccine within 28 days of inoculation for group 1 and 
within 56 days of inoculation for group 2 
 
 STUDY VISITS AND PROCEDURES  
 
An overview of the study visits, evaluation schedule, and specimen collection is  provided  in 
Appendix II  and Appendix II I. This section contains additional information on visit-specific study 
procedures.  
 
34 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119803] be performed at one of the clinical sites. Unless otherwise 
specified, visits may be split, with required procedures performed on more than one day within 
the allowable visit window. All clinical tasks will be perform ed by a medical professional. The 
physical examination will include temperature, heart rate, respi[INVESTIGATOR_697], assessment of ears, eyes, nose, and throat (EENT), lungs, heart, and skin, as well as abdominal, musculoskeletal, and, 
as appropriate , neurologic al exam s. A focused clinical examination will include temperature, 
heart rate, respi[INVESTIGATOR_697], EENT, lung, heart and lymph nodes assessment . 
 
All specimens will be obtained, processed, stored and transferred per the MOP.  
 
In addition to the protocol -specified procedures listed in this section, study staff may complete 
other tasks consistent with SOPs, including but not limited to collecting, reviewing, and updating demographic and locator information; reviewing elements of informed consent; scheduling 
telephone contacts and visits; providing instructions for contact[CONTACT_133037]; 
providing visit reminders; and following up on missed visits. All visit procedures will be 
documented in accordance with the MOP. Refer to Section 10 for more information on 
documentation requirements and completion of case report forms ( CRFs ).  
 
The study’s medical professional will inform parent/guardian of any significant abnormal 
physical findings and, after obtaining parental release of information, will make appropriate 
referrals back to the child’s primary caregiver, if necessary.   
35 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 
 CONSENTING PROCESS           
 
The screening  process may be completed under a separate screening protocol and consent or 
under the study protocol and consent. The parent/guardian must complete the informed consent 
process and sign the informed consent document ( ICD) before screening or study procedu res are 
performed. The consenting process for the study may take place during the screening visit or may be conducted at a separate visit. During the consenting process, the child’s parent will review the ICD, be encouraged to ask questions, and complete a comprehension assessment to evaluate 
consent understanding. Study staff will use incorrect answers from the comprehension assessment 
to identify areas of the ICD that need further review with the parent/guardian. This will help 
ensure that the parent/guar dian has sufficient understanding of the process before the ICD is 
signed. Parent/guardian will be offered a copy of the ICD. 
 
For group 2, enrollment into the second RSV surveillance period will be initiated under a separate 
consent from the ICD used for the primary study.  
During the consenting process, the parent will be given the opportunity to provide permission for use of their child’s pi[INVESTIGATOR_322032], articles, or presentations. In addition, the 
parent will be given the opportunity to provide permission for storing their child’s specimens for 
future respi[INVESTIGATOR_322033].  
 As needed, a parent/guardian will complete a Health Insurance Portability and Accountability Act (HIPAA) medical record release to allow study staff to review medical history  and immunization 
records, and to allow review of AEs  during the study. Only those portions of the medical record 
that are pertinent to the study will be maintained in the study chart.  
 
 SCREENING VISIT 
 The screening process will include reviewing  the medical record, obtaining a medical history 
from parent/guardian, and conducting a physical examination. The medical record review should 
include review of history related to the study eligibility criteria, the immunization record , and 
growth chart data. T he medical history from the parent should include demographics, prior 
diagnoses, current medications, signs and symptoms, developmental status , age of household 
members, day care attendance, and use of medications prior to inoculation . 
 
The s creening visit will also include obtaining a  serum  sample to test for the presence of RSV 
antibod ies. Approximately 5 mL of blood is sufficient quantity for the screening and pre-
inoculation assays. The procedure will be performed  and documented per the SOP. As in previous 
phase I trials of other live-attenuated RSV vaccines ( 11, 23-25), other screening laboratory tests 
will not be performed on the participant . Such tests are not routinely performed as part of well-
child care, given that the risk of undiagnosed hepatic, metabolic, and renal diseases is much lower 
in children than in adults  (36).  
 
For the RSV -seropositive participants, the screening serum sample must be obtained in the same 
calendar year as study inoculation. The pre -inoculation serum antibody sample must be obtained 
no more than [ADDRESS_1119804] be obtained no  more 
than 42 days prior to inoculation. Study staff should consider potential randomization and 
inoculation dates when scheduling the p articipant  screening visit s. 
 
36 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 Table 3: Screening Visit Procedures  
Screening Visit Procedures  
Administrative  Tasks  
 • Conduct consenting process  
• Confirm parent/guardian’s  informed consent comprehension  
• Obtain release of medical records as required per HIPAA  
• Obtain available medical records  
• Assess eligibility  
•  
Clinical Tasks  • Obtain , review , and document medical history  
• Perform complete physical examination , or 
physical examination m ay be deferred until study day 0  
• Address any concerns  
• Document findings  
• Obtain and r eview participant’s immunization record  
• Review participant’s medical records to determine a ge-appropriate 
developmental  assessment, and  participant’s weight and length  
Laboratory  
Tasks  Blood  Collect blood for : 
• Screening1 and pre -inoculation2 samp le for RSV serum antibody testing  
Follow -up Preparation  • Schedule enrollment visit  
1. Obtained within the same calendar year as inoculation for RSV -seropositive participants and no more than 
[ADDRESS_1119805] (DSMB) Executive Secretary. Unblinded 
laboratory personnel will label the vaccine syringes with the study virus vaccine name, PI [CONTACT_10573], study number, subject’s randomization number, preparer and vaccine verifier’s initials and 
expi[INVESTIGATOR_4389]. The vaccine administrator and verifier will initial the label and place the 
label in the subject’s study chart. The vaccination time will be documented on the vaccine 
administration record (VAR). All syringes will be disposed of by [CONTACT_809795]. A  copy of the VAR will be sent to the laboratory . 
  A copy of the randomization code will be retained by [CONTACT_809796]. Without the PI's written request to unblind, t he randomization code 
will not be released to the clinical staff until the acute monitoring phase is complete for each subject within the randomization group. Pediatric subjects will be block-randomized in groups of 3 (2 vaccinees and 1 placebo recipi[INVESTIGATOR_322034]); this allows for maintenance of the blind during 
each subject’s acute monitoring phase but also provides early information regarding safety, which 
is appropriate and common practice for phase 1 respi[INVESTIGATOR_322035] ( 11,23,25). 
Detailed procedures for randomization and unblinding will be placed in the laboratory study binder. 
  
37 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 
 ENROLLMENT  
 
6.4.1 Enrollment  - Inoculation (Day 0) 
Enrollment will occur between April [ADDRESS_1119806] include the information 
outlined in the MOP.   
 The ICD will be  obtained from the parent/ guardian of each child who participates in this study 
prior to the performance of any study procedures or inoculation. If not previously obtained, then the ICD will be completed on the day of enrollment. T he child’s parent /guardian will be 
encouraged to ask questions and complete a comprehension assessment  to evaluate understanding 
of the study. Study staff will use incorrect answers from the comprehension assessment  to identify 
those areas of the ICD that need further review with the parent/guardian. This will help  ensure that 
the parent/guardian has sufficient understanding of the study process before the ICD is signed.  
 If the participant is noted to have any of the following on enrollment day, inoculation must be 
deferred: 
• fever ( temporal or rectal temperature o f ≥ 100.4°F), or  
• URI or LRI symptoms or signs (including but not limited to rhinorrhea, cough, or 
pharyngitis), or 
• nasal congestion significant enough to interfere with successful inoculation, or  
• otitis media.  
 
If the  inoculation for an RSV-seropositive participant has to be deferred to the following calendar 
year, or if the [ADDRESS_1119807]  be rescreened.  
38 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
  
Table 4: Enrollment Visit Procedures  
Enrollment Visit Procedures (Day 0)*   
Administrative Tasks  
 • Confirm study ICD is completed and signed and dated by [CONTACT_809797]/guardian and study staff who completed the consenting process  
• Complete eligibility determination and confirmation  
• Complete paper -based eligibility checklist 
• Obtain release of medical records as required per HIPAA  
Clinical Tasks  • Obtain interim history  from parent/guardian  
• Perform physical exam:  
o Complete physical exam if deferred at screening, OR  
o Focused physical exam if physical completed at 
screening  
• Address any concerns  
• Document findings  
• Confirm eligibility  
Laboratory 
Tasks Blood  If insufficient volume obtained at screening, collect blood for : 
• Pre-inoculation RSV antibody titer  
Nasosorption SAM Strip 
and/or Nasal 
Wash  Collect nasosorption strip for:  
• RSV antibody assays  
Note: The nas osorption must be perform ed prior to  the nasal wash.  
The nasal wash must be obtained prior to administering the study 
product.  
Collect nasal wash for:  
• RSV antibody assays  
• RSV viral detection and quantification  
Study Product Administration  • Administer study product and maintain participant in a supi[INVESTIGATOR_131962] 1 minute  
• Observe for approximately 30 minutes after inoculation to evaluate for 
immediate hypersensitivity reactions  
Follow -up Preparation  • Provide the following: temperature card with explanation, temporal and 
rectal thermometers with instructions for use, illness criteria 
explanation, and study personnel contact [CONTACT_3031]  
• Schedule non- visit day  contact [CONTACT_809798]-person visit 
• Offer parent/guardian safety seat education materials, and a safety seat 
educator appointment  
• Offer parent lactation services by a certified lactation counselor, if 
appropriate  
*Within same calendar year as screening for RSV -seropositive participants , and n o more than 42 days from 
screening for RSV -seronegative participants  
 
Following the inoculation day visit, the parent/guardian will record the infant/child’s 
temperatures and signs of illness on the temperature card and provide these to study personnel 
during an in-person visit or non- visit day contact. New rectal thermomete rs will be given and 
temporal artery thermometers will be provided to parent/guardian for use during the study. For 
temperature measurements, parent/guardian will be instructed to use the study -provided temporal 
artery thermometer to screen for elevated te mporal artery temperatures. This device is used to 
minimize the number of rectal temperature measurements and has been shown to be an effective 
screening tool for rectal fever ( 37). The parent/guardian will measure temporal artery 
temperatures following the manufacturer’s directions. If any temporal artery temperature is 
≥ 100.0°F, parent/guardian will be asked to measure a rectal temperature within 20 minutes (37). 
For study- specific manage ment and grading of temperatures, see Section 8, Table 22. 
 
39 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
  
6.4.2 Enrollment in the Second Season of RSV Surveillance (Group 2  Only) 
 
Participation in RSV surveillance for a second season will require completion of an additional 
consent document  by [CONTACT_114788]. The consent document for this optional portion of the 
study may be done at the pre–RSV second seasonal surveillance visit or at a separate visit prior to 
the pre –RSV second seasonal surveillance visit.  
 
 STUDY  PHASE S  
 
Refer to Figures 1 and 2  for timeline s of study visits. The Acute Phase begins with inoculation 
and ends at midnight on the 10th day after inoculation for RSV-seropositive participants, and at 
midnight on the 28th day after inoculation  for RSV -seronegative participants. During the Acute 
Phase of the study, a study healthcare professional  will be available by [CONTACT_756] 24 hours a day 
for consultation with parent/guardian regarding any illnesses that may occur.  
Study personnel will have daily contact [CONTACT_809799] -seropositive participant s’ parents/guardians for 
the first [ADDRESS_1119808] 28 
days after inoculation. This 28-day period is consistent with the duration of shedding of live-attenuated respi[INVESTIGATOR_327909] i n RSV- seronegative participants  (28, 37-39) .  
  
On non-visit days, study staff will contact [CONTACT_7071]/guardian and will record the 
parent/guardian- provided temperatures and signs of illness. Participants with illness may have 
additional visits to assess t he illness ( Section 6.8, Illness Visit) . 
 
6.5.1 RSV-S eropositive Children  (Group 1) 
[IP_ADDRESS] Acute Phase: In-person Study Visit Days  
 
An in -person study visit and clinical assessment performed by a healthcare professional will be 
completed during visits on days 3, 4, 5, 6, 7, and 10 after inoculation, with a visit window of ± 1 day. If an in- person visit is moved by ± [ADDRESS_1119809] of the original interim visit date.  
 
Table 5: Acute Phase In -Person Visit Procedures – RSV- Seropositive Children  
Days 3,  4, 5, 6, 7 and 10 In -person Visit Procedures (each visit ± 1 days)  
Clinical Tasks  • Obtain and document from parent/guardian the participant’s 
previous days’ interim history including:  
 medications and/or immunizations  
 signs and symptoms of illness  
 highest temperature reading, indicate temperature method    
• Perform focused clinical examin ation  
• Address any concerns  
• Review safety data 
• Document findings  
Laboratory 
Tasks Nasal wash   Collect nasal wash for:  
• RSV viral detection and quantification  
Follow -up Preparation  • Schedule non -visit day  contact [CONTACT_138563] -up, in-person visits  
Day 10 only:  
• Review SAE criteria with participants and how  to contact [CONTACT_809800] -Acute Phase  
40 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 During an Acute Phase study visit, i f the participant  is diagnosed with or suspected of  having 
URI, LRI, otitis media or  fever ( as defined in Appendix IV ), testing of the nasal wash specimen 
for adventitious a gents will be performed as described in the MOP .  
[IP_ADDRESS] Acute Phase: Non -Visit Study Day Contacts 
 
In the [ADDRESS_1119810] will be made on days that an in-person visit 
is not completed : days 1, 2, 8, and 9 (each visit ± 1 day) . On non-visit days, study staff will 
contact [CONTACT_7071]/guardian and will record the parent/guardian -provi ded temperatures and signs 
of illness. Participants with illness may have additional visits to assess the severity of the illness (Section 6.8). 
 
Table 6: Acute Phase Non -Visit Contact [CONTACT_322096] – RSV- Seropositive Children  
Days 1, 2, [ADDRESS_1119811] Procedures (each visit ± 1 day)  
Clinical Tasks  • Obtain and document from parent/guardian the participant’s 
interim history from previous days , including:  
 medications and/or immunizations  
 signs and symptoms of illness  
 highest temperature reading, indicate temperature method  
• Address any concerns  
• Review safety data 
• Document findings  
Follow -up Preparation  • Schedule an illness appointment if necessary  
 
[IP_ADDRESS] Study Day [ADDRESS_1119812] with the family on Day 11. 
 
Table 7: Day 11 Non- Visit Procedures – RSV -Seropositive Children  
Day 11 Non-Visit Procedures  
Clinical Tasks  • Obtain and document from parent/guardian the participant’s 
previous days’ interim history including:  
 medications and/or immunizations  
 signs and symptoms of illness  
 highest temperature reading, indicate temperature method  
• Address any concerns  
• Review safety  data 
• Document findings  
Follow -up Preparation  • Review SAE criteria with participants and how  to contact [CONTACT_809800] -Acute Phase  
 
  
41 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 [IP_ADDRESS] Post-Acute Phase  
 
The Post -Acute Phase begins on the 11th day after inoculation and ends on the 28th day after 
inoculation. During the Post-Acute Phase, parent/guardian will be instructed to monitor for and 
contact [CONTACT_809801] a SAE. If the parent 
reports an  SAE that may meet the study pause or stop criteria (Section  8.3), then an Illness Visit  
will be scheduled  (Section 6.8). 
 
[IP_ADDRESS] Study Day [ADDRESS_1119813]- Acute Phase.  
 
Table 8: Day 28 Visit Procedures – RSV- Seropositive Children  
Day 28  Visit (+7 Days)  
Administrative Tasks  • Provide study compensation  
Clinical Tasks • Obtain and document from parent/guardian the participant’s interim 
history from midnight of the 10th day through the  28th day 
following inoculation , including:  
 visits to medical provider/hospi[INVESTIGATOR_602]  
 medications and/or immunizations  
 signs and symptom s of illness  meeting SAE criteria  
• Address any concerns  
• Review safety data 
• Document findings  
Laboratory  
Tasks Blood  Collect blood for:  
• Serum antibodies to RSV  
Nasosorption 
SAM Strip 
and/or Nasal 
Wash  Collect nasosorption strip for:  
• RSV antibody assays  
Note: The nasosorption must be performed prior to the nasal wash.  
The nasal wash must be obtained prior to administering the study 
product.  
Collect nasal wash for:  
• RSV antibody assays  
 
6.5.2 RSV-S eronegative Infants and Children 
[IP_ADDRESS] Acute Phase: In-person Study Visit Days  
 
An in -person study visit and clinical assessment performed by a healthcare professional will be 
completed during visits on Study Days 3, 5, 7, 10, 12, 14, 17 and 28 after inoculation with a visit 
window of ±  1 day. If an in -person visit is moved by ± [ADDRESS_1119814] of the original interim visit date.  
  
42 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 Table 9: Acute Phase In -Person Visit Procedures – RSV- Seronegative Children  
Days 3, 5, 7, 10, 12, 14, 17, and 28 In -person Visit Procedures (each visit ± 1 days)  
Clinical Tasks  • Obtain and document from parent/guardian the participant’s 
previous days’ interim history including:  
 medications and/or immunizations  
 signs and symptoms of illness  
 highest temperature reading, indicate temperature method    
• Perform focused clinical examin ation  
• Address any concerns  
• Review safety data 
• Document findings  
Laboratory 
Tasks 
Nasal Wash 
and/or  
Nasosorption 
SAM Strip Collect nasal wash for:  
• RSV viral detection and quantification  
Day 28 only : Collect nasal wash for:  
• RSV antibody assays  
• RSV viral detection and quantification  
Day 28 only : Collect nasosorption strip for :  
• RSV antibody assays  
Note: The nas osorption must be perform ed prior to  the nasal wash.  
Follow -up Preparation  • Schedule non -visit day  contact [CONTACT_138563] -up, in-person visits  
Day 28 only :  
• Review SAE criteria with participants and how  to contact [CONTACT_809800] -Acute Phase  
[IP_ADDRESS] Acute Phase: Non -Visit Study Day Contacts 
 
In the [ADDRESS_1119815] will be made on days that an in -person visit 
is not completed : days 1, 2, 4, 6, 8, 9, 11, 13, 15, 16, and 18–27 (each visit ± 1 day) . On non- visit 
days, study staff will contact [CONTACT_7071]/guardian and will record the parent/guardian-provided 
temperatures and signs of illness.  Participants with illness may have additional visits to assess the 
severity of the illness ( Section  6.8). 
 
Table 10: Acute Phase Non -Visit Contact [CONTACT_322096] – RSV- Seronegative Children  
Days 1, 2, 4, 6, 8, 9, 11, [ADDRESS_1119816]  Procedures 
(each visit ± 1 day)  
Clinical Tasks  • Obtain and document from parent/guardian the participant’s 
previous days’ interim history including:  
 medications and/or immunizations  
 signs and symptoms of illness  
 highest temperature reading, indicate temperature method  
• Address any concerns  
• Review safety data 
• Document findings  
Follow -up Preparation  • Schedule an illness appointment if necessary  
 
  
43 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 [IP_ADDRESS] Study Day [ADDRESS_1119817] with the family on Day 29. 
 
Table 11: Day 29 Non- Visit Procedures – RSV -Seronegative Children  
Day 29 Non -Visit Procedures  
Clinical Tasks  • Obtain and document from parent/guardian the participant’s 
previous days’ interim history including:  
 medications and/or immunizations  
 signs and symptoms of illness  
 highest temperature reading, indicate temperature method  
• Address any concerns  
• Review safety data 
• Document findings  
Follow -up Preparation  • Review SAE criteria with participants and how  to contact [CONTACT_809800] -Acute Phase  
 
[IP_ADDRESS] Post-Acute Phase  
 
The Post-Acute  Phase begins on the 29th day after inoculation and ends on the 56th day after 
inoculation. During the Post -Acute Phase, parent/guardian will be instructed to monitor for and 
contact [CONTACT_809802] a SAE . If the 
parent reports an SAE that may meet the study pause or stop criteria (Section  8.3) then schedule 
an Illness Visit ( Section 6.8). 
 
[IP_ADDRESS] Study Day [ADDRESS_1119818]- Acute Phase.  
  
44 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 Table 12: Day 56 Visit Procedures – RSV -Seronegative Children  
Day 56 Visit (+7 Days)  
Administrative Tasks  • Provide first study compensation payment  
Clinical  Tasks  • Obtain and document from parent/guardian the participant’s 
interim history from  midnight of the 28th day through the 56th day 
following inoculation , including:  
 visits to medical provider/hospi[INVESTIGATOR_602]  
 medications and/or immunizations  
 signs and symptoms of illness  meeting SAE criteria  
• Address any concerns  
• Review safety data 
• Document findings  
Laboratory  
Tasks 
 Blood  Collect blood for:  
• Serum antibodies to RSV  
Nasosorption 
SAM Strip 
and/or Nasal 
Wash  Collect nasosorption strip for:  
• RSV antibody assays  
• Note: The nasosorption must be performed prior to the nasal wash.  
The nasal wash must be obtained prior to administering the study 
product.  
Collect nasal wash for:  
• RSV antibody assays  
Follow -up Preparation  Follow -up depends on when, during the calendar year, the Day 56 
Visit is conducted.  If Day 56 Visit  is conducted: 
• Prior to October 1  
 schedule Pre- RSV Season Visit ( Section  6.6.1) 
• On or after October 1  
 Day 56 Visit will a lso be the Pre -RSV Season Visit  
 Review plans for weekly contact [CONTACT_809803] ( Section  6.6.2 ) 
 
[IP_ADDRESS] Period after Day [ADDRESS_1119819] with the participant is not required except for the Pre -RSV Season 
Study Visit described in Section 6.6.1 . No clinical data will be recorded on CRFs or reported 
under this protocol  except for data as outlined in Section 7.2. 
 
 RSV  SURVEILLANCE : FIRST SEASON  
 
6.6.1 Pre-RSV Season  Surveillance Study Visit  
 
The Pre -RSV Season Study Visit is not required if the Day 56 Visit is conducted on or af ter 
October 1; the sample s collected at the Day 56 Visit are sufficient for the Pre -RSV Season Study 
Visit. Otherwise, an  in-person visit  is expected of participants during the Pre- RSV Season for 
collection of a blood sample,  nasal wash sample  and/or nasosorption strip for RSV antibody 
assays.   
45 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 Table 13: Pre-RSV Season Surveillance Study Visit Procedures  
Pre-RSV Season Study Visit (October 1  through October  31 of enrollment year ) 
Clinical Tasks  • Document findings related to study procedure  
Laboratory  
Tasks 
 Blood  
 Collect blood for:  
• Serum antibodies to RSV  
Nasosorption 
SAM Strip 
and/or Nasal 
Wash  Collect nasosorption strip for:  
• RSV antibody assays  
• Note: The nasosorption must be performed prior to the nasal wash.  
The nasal wash must be obtained prior to administering the study 
product.  
Collect nasal wash for:  
RSV antibody assays  
Follow -up Preparation  • Review plans for weekly contact [CONTACT_809804] (see Section  6.6.2 ) 
 
6.6.[ADDRESS_1119820] for Surveillance during the RSV S eason  
 
Based on previous data regarding the seasonality of RSV in the Baltimore, MD , area ( Appendix 
IV, Figure 6 ), surveillance for RSV -associated disease will be conducted between November [ADDRESS_1119821] RSV season may overlap with the Acute 
and/or  Post -Acute study phases. In this case, all evaluations required for each of the relevant 
phases of the study will be conducted.  
 
During the first RSV season  following receipt of study product, participant s enrolled in this study 
will be monitored for symptomatic, medically attended, RSV -like illnesses listed below  via 
weekly telephone or email communication or an in-person visit . (Rhinorrhea and cough need not  
meet the Appendix I V criteria  if they are documented by [CONTACT_322127] ): 
• Medically attended fever  
• Medically attended URI  
• Medically attended otitis media  
• Medically attended LRI  
 
An Illness  Visit will be scheduled within 3 days of study staff notification of any of these events 
(Section  6.8).  
 
Table 14: RSV Season Surveillance Procedures  
RSV Season Surveillance (November 1 through March 31 following inoculation)  
Clinical  Tasks  • Obtain interim history  
• Review safety data 
• Document findings  
Follow -up Preparation  • Continue with weekly contacts through March 31  
• Schedule an Illness Visit if warranted  
• Schedule the Post-RSV Season Study Visit (targeted  April 1 st - 
April  30th with allowable window  through Septe mber 30 th) 
 
46 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119822] and April 30th through September 30th . 
 
Table 15: Post-RSV Seasonal Surveillance Study Visit Procedures  
Post -RSV Season Study Visit  
Administrative Tasks  • Provide second study compensation  
Clinical  Tasks  • Document findings related to study procedure s 
Laboratory  
Tasks 
 Blood  
 Collect blood for:  
• Serum antibodies to RSV  
Nasosorption 
SAM Strip  Collect nasosorption strip for:  
• RSV antibody assays  
 
 
 
 RSV  SURVEILLANCE : SECOND SEASON  
 
The second RSV s easonal surveillance is November 1 through March 31 in the second season 
following inoc ulation and will be optional for RSV- seronegative children ( group 2) who have 
participated in the first surveillance season . An ICD for the second season of RSV surveillance 
must be signed before any procedures are performed. If a participant’s parent/guardian agrees to 
have their child participate in a second season of RSV surveillance, the procedures for the second 
season wil l be identical to those outlined for the first season in Section 6.[ADDRESS_1119823] occur depends on the study 
phase and the grading of the fever and respir atory symptoms per Section 8.2  and If the Illness 
Visit occurs on a day concurrent with an in-person study visit, a single nasal wa sh collection is 
required and adventitious agent testing will be requested. All sympt oms will be followed until 
resolution or deemed stable or chronic by [CONTACT_809805] (e.g., medical doctor or nurse practitioner). Illness Visits may occur during any of the study phases. 
 
If the acute or post- acute phases overlap the surveillance p eriod (between November 1 and March 
31), then the timelines for the acu te and post -acute phases will be used.  
47 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
   
Table 16: Illness Visit Timeframe  
Illness Visit Timeframe  
Phase  Symptoms  Grade  Visit Timeframe  
Acute  Fever, otitis media or URI  1 Within 3 days  
Acute  Fever, otitis media or URI  ≥ [ADDRESS_1119824] -Acute  SAE  that meets study pause 
or stop criteria ( Section  8.3) ≥ 2 Within 3 days 
RSV Season 
Surveillance  Medically attended fever, 
otitis media, URI or LRI  ≥ 2 Within 3 days  
 
Table 17: Illness Visit Procedures  
Illness Visit Procedures  
Administrative Tasks  • Complete Adventitious Agent Assay Request for rRT -PCR on 
nasal wash for adventitious agents  
Clinical  Tasks  • Obtain and document from parent/guardian the participant’s 
interim history including:  
 medications and/or immunizations  
 signs and symptoms of illness  
 highest temperature reading, indicate temperature method    
• Perform focused clinical examination  
• Address a ny concerns  
• Review safety data 
• Document findings  
Laboratory  
Tasks  Nasal Wash  Collect nasal wash for:  
• Viral detection and quantification  
Follow -up Preparation  • Schedule follow -up as appropriate  
 
 EARLY DISCONTINUATION  STUDY  VISIT 
 
In the event that a child is unable to continue participation in the study, parent/guardian will be 
encouraged to allow the participant to complete safety monitoring through Day 28 for RSV-
seropositive participants and through Day 56 for RSV -seronegative participants.  E very effort 
should be made to schedule a final Early Discontinuation Visit. 
48 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
  
Table 18: Early Discontinuation Procedures  
Early Discontinuation  
Administrative Tasks  • Record data on CRF  
Clinical  Tasks  • Obtain interim history  
• Address any concerns  
• Review safety data 
• Encourage parent/guardian to allow the participant to complete 
safety monitoring through Day 28 for RSV -seropositive 
participants  and through Day 56 for RSV -seronegative participants  
• Document findings  
Laboratory  
Tasks 
 Blood  Collect blood for:  
• Serum antibodies to RSV  
Nasal Wash  
and/or 
Nasosorption SAM Strip If Early Discontinuation Visit is within 28 days of inoculation for 
RSV-seropositive participants or 56 days for RSV -seronegative 
participants  (Appendix II), collect nasal wash for:  
• Viral detection and quantification  
• RSV antibody assays  
Collect nasosorption strip for : 
• RSV antibody assays  
Note: The nas osorption must be perform ed prior to  the nasal wash.  
 
 LABORATORY PROCEDURES  
 
6.10.1 Specimen Collection  
 
Specimens will be collected for this study as indicated in the Schedule of Events. Further 
information on collection of blood and nasal wash specimens will also be provided in the MOP.   
6.10.2 Virus Detection  
 
Specimens for viral culture and quantification of vaccine virus shedding will be obtained by [CONTACT_809806] 20 mL of Ringer’s lactate solution once before and approximately 6 
times after inoculation fo r RSV-seropositive participants and approximately  8 times after 
inoculation RSV -seronegative participants as shown in Appendix II . These specimens may also 
be tested for adventitious respi[INVESTIGATOR_809734]. Additional nasal wash specimens for 
detection of RSV and adventitious respi[INVESTIGATOR_809735]- PCR will also be 
obtained from participants who meet illness criteria during the initial phase (Day 0 through Day 
28 for RSV- seropositive participants ; Day 0 through Day 56 for RSV- seronegative participants) 
as well as during the RSV  First Seasonal  Surveillance Period (November 1 – March 31) for all 
RSV-seronegative participants and the RSV Second S eason  Surveillance for RSV -seronegative 
participants whose parent s/guardian s elect to participate. If a participant  becomes ill  during the 
Acute or Post-Acute Phase, then up to 10 additional nasal w ashes over a 28-day period  for group 
1 participants and over a 56- day period for group 2 participa nts may be obtained to exclude 
infection with an adventitious virus. Laboratory testing will be performed by [CONTACT_809807].  
 
49 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 6.10.3 Immunologic Assays 
 
For measurement of RSV serum antibodies, s erum specimens will be obtained in 
RSV- seropositive children not more than 56 days prior to inoculation and on D ay 28 (+7)  
postinoculation; and in RSV -seronegative infants and children not more than 42 days prior to 
inoculation and on Day 56 ( +7) postinoculation. In addition, pre- first RSV season and post -first 
RSV season serum specimens will be collected  in all RSV -seronegative infants and children . 
These samples will be used to  determine whether a four- fold or greater rise in antibody titer h as 
occurred during the first RSV season, which would signify infection with wt RSV. This will 
allow comparison of the rate and severity of significant RSV illness following infection with wt 
virus, as well as comparison of the antibody responses, in vaccin e and placebo recipi[INVESTIGATOR_840].   
 
For subjects in group 2 enrolled in surveillance during the second RSV season, RSV 
neutralizing antibodies will also be measured in serum specimens collected before and after the second RSV season:  between October 1 and October 31 (pre -season 2) , and with a target 
window of  April 1 to April  30 which can be extended through September 30 (post- season 2). 
This will allow assessment of the duration of antibody responses to vaccination, and 
comparison of the rate and severity of significant RSV illness following infection with wt virus 
in vaccine and placebo  recipi[INVESTIGATOR_809736] n. 
 
Specimens will be obtained by [CONTACT_48571], finger- stick, or heel -stick. No more than 5 mL of 
blood will be drawn at each blood draw visit. A maximum of 10 mL of blood will be taken from RSV- seropositive subjects for study purposes. A maximum of 20 mL of blood will be taken from 
RSV-seronegative subjects for study purposes  from screening through season 1 surveillance. A 
maximum of an additional 10 mL of blood will be taken from RSV-seronegative subjects who 
participate in season 2 surveillance.  
 For RSV -seropositive participants , nasal wash specimens and/or nasosorption strips  for 
measurement of secretory immunity will be obtained before inoculation and 28 days after 
inoculation. For RSV- seronegative participants, nasal wash specimens and/or nasosorption  strips 
for measurement of secretory immunity will be obtained before inoculation, [ADDRESS_1119825] -RSV season 1 surveillance visits.  These specimens may be 
generated from the same nasal wash obtained for viral culture, but specimen processing is different as described in the MOP.  If the parent/guardian opts to participate in the second year of 
RSV surveillance, a nasal wash specimen and/or nasosorption strip will also be obtained at the 
second year pre- and post- RSV surveillance visits to measure secretory immunity .    
 
6.10.4 Specimen Preparation, Testing, Storage, and Shippi[INVESTIGATOR_132896], transported, processed, tested, stored and/or 
shipped in accordance with SOPs. The frequency of specimen collection and testing will be 
directed by [CONTACT_322133] ( Appendix II  and Appendix III ).  
 
6.10.[ADDRESS_1119826]. Nasosorption assays will be performed at the LID,  NIAID. 
Cytokine/chemokine assays may also be performed on nasal washes from participant s infected 
with vaccine virus if sufficient material is available. Selected specimens may be sent  to LID, 
NIAID for confirmatory testing.   
50 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
  
6.10.6 Plan for Use and Storage of Biological Samples 
 
All specimens collected as part of this study may, with the parent/guardian’s permission, be 
stored for future research as part of CIR’s approved biospecimen repository for vaccine research. 
These samples and data may be used for future screening for respi[INVESTIGATOR_809737]. The parent/guardian or child will not own 
the blood specimens, nasal fluid, or data after it is given to the study. No financial benefit will be provided to the parent/guardian or child from any product or idea created by [CONTACT_809808]. These samples will not be sold or used to make commercial products. 
Genetic tests will not be performed on these samples unless separate informed consent is 
obtained.  
 
Samples stored in the repository will be labeled  with the study identification number  of the 
participants  that, by [CONTACT_1029], cannot identify study participants  but are linkable to the study 
databases generated by [CONTACT_1030]. The repository database will contain only the study 
participants’  numbers. A master log linking the  study participants’  identification number s to their 
names  is maintained by [CONTACT_1758]’s  clinical staff  in a password- protected computer system with 
limited access to authorized research team members and will not be shared with the laboratory.  
Study participants, or their parents/guardians, may withdraw consent for future testing of their 
specimens at any time.  
 
6.10.[ADDRESS_1119827] with contaminated needles, blood, and blood products, appropriate blood and secretion precautions will be employed 
by [CONTACT_214148]. The procedures for obtaining, shippi[INVESTIGATOR_007] , and handling of all specimens for this 
study will follow the cu rrent recommendation of the Centers for Disease Control  and Prevention 
(CDC)  and the NIH . All infectious specimens will be transported using packaging mandat ed in 
Title 42 of the Code of Federal Regulations (CFR) , Part 72 (42 CFR 72) and in accordance with 
individual carrier guidelines (e.g., Federal Express ). 
 
 SAFETY ASSESSMENT , MONITORING,  AND REPORTING  
 
Participant safety will be carefully assessed, monitored, and reported at multiple levels 
throughout this study. Sections 7.1-7.[ADDRESS_1119828] (DSMB ) are briefly referenced in Section 7.1.[ADDRESS_1119829]’s study participants and for alerting 
the protocol t eam if unexpected concerns arise. Trained  study staff will record safety -related data 
on CRFs as indicated in Section 7.2. The PI  [INVESTIGATOR_809738] (UPs) involvin g risks to 
participants or others.  
 
51 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 7.1.2 Safety Review and Communications Plan (SRCP)  
A Safety Review and Communication Plan (SRCP) was developed for the protocol. The SRCP is 
an internal communications document between the PI  [INVESTIGATOR_322052] (OCRPRO) Cli nical 
Safety Office , which delineates the safety oversight responsibilities of the PI, the CSO, and other 
stakeholders. The SRCP also includes the overall plan for conducting periodic safety surveillance 
assessments.   
 
7.1.3 Sponsor Medical Monitor 
 
A medical monitor representing the IND sponsor (OCRPRO) has been appointed for oversight of 
safety in this clinical study. The sponsor medical monitor will be responsible for performing 
safety assessments as outlined in a Safety Review and Communications P lan (SRCP).  
 
7.1.[ADDRESS_1119830] 
 
An independent DSMB  will monitor participant safety through routine and as-needed reviews of 
study data . Refer to Section  9.4.2 for more information on t he composition and role of the DSMB 
in the monitoring of this study.   
 
7.1.5 Sponsor  Reporting  
 
A S[LOCATION_003]R is a suspected adver se reacti on that is  both serious and unexpe cted, as defined in 21 
CFR 312.32. S[LOCATION_003]Rs  will be reported to the FDA and all participating investigators as IND 
Safety Reports.  The Regulatory Sponsor will also submit a brief report of the progress of the 
investigation to the FDA on an annual basis as defined in 21 CFR 312.33. 
Following notification fr om the PI, OCRPRO, as the IND Sponsor, will report all SAEs to the 
FDA within the required timelines. Fatal and life -threatening events will be reported within 
7 calendar days of the sponsor’s awareness and all other SAEs will be reported within 15 calenda r 
days of the sponsor’s awareness.  
 
 SAFETY -RELATED RECORDING ON CRF S 
 AEs that occur during protocol-specified AE reporting periods following inoculation  of study 
product should be considered AEs. The current section outlines which events should be collec ted 
on source documents and which should be recorded on CRFs for inclusion in the database. 
 
AEs may be observed by [CONTACT_3437] , elicited  or volunteered from the 
parent/guardian or participant, or captured on participant ’s temperature cards. Assessment of 
safety will include clinical observation and monitoring of laboratory parameters as necessary . 
Follow-up measures such as history, physical examination, and laboratory testing and/or 
treatment may be necessary if a particip ant experiences an AE. Details of AEs will be properly 
documented on the source documents, recorded on CRFs, and reported  to LID investigators and 
the DSMB in separate semi -annual and annual reports. AEs will be provided to the IRB as 
defined by [CONTACT_322141].  
 
This study has several periods of AE observation that have different AE CRF recording 
requirements. In addition, for RSV -seronegative participants, there may be a period when no AEs 
are recorded on CRFs if the Day 56 Visit occurs in advance of the start of the RSV Season 
Surveillance Period (November 1). The AEs  (solicited and unsolicited; and SAEs) to be recorded 
on CRFs and the study phase and the calendar dates during which they are to be reported are defined in Table 19 and Table 20.  
52 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119831] results, and diagnoses, as shown in  
Table 19 and Table 20.  
  
53 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
  
 
Table 19: AE CRF Recording Requirements for RSV -Seropositive Subjects  
Study Phase at the Time of Event 
Onset Calendar 
Date  AEs to Record on CRFs  Concomitant Medications to 
Record on CRFs  
Day 0 through midnight of 10th day 
following inoculation  
(Acute Phase)  ANY  • All SAEs  
• All solicited AEs that meet 
Appendix I V, criteria  
• All unsolicited AEs (Grades 1 to 4), with the exception of the following conditions if not 
treated with prescription 
medication or non- prescription 
medications with antipyretic 
properties: diaper rashes, teething pain, and spi[INVESTIGATOR_809739]:  
 
• All cough and cold remedies 
including decongestants, cough 
suppressants, expectorants  
• All nasal sprays (except saline 
spray)  
• All antihistamines  
• All antip yretics  
• All prescription medications  
 For SAE s and LRIs:  
• All medications related to the 
recorded event  
From the 11th day after inoculation 
to the 28th day after inoculation  
(Post -Acute Phase)  ANY  • All LRIs and SAEs  
 
 • All medications related to the 
recorded event  
Throughout study  ANY  • Unresolved AE s or SAE s with 
onset from  Day 0 to midnight on 
the 10th day after inoculation  
• Unresolved LRIs and SAE s with 
onset prior to the 28th day 
following inoculation  
•  • All medications related to the 
recorded event  
 
  
54 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
  
Table 20: AE CRF Recording Requirements for RSV -Seronegative Subjects  
Study Phase at the Time of Event 
Onset Calendar 
Date  AEs to Record on CRFs  Concomitant Medications to 
Record on CRFs  
Day 0 through midnight of 28th day 
following inoculation  
(Acute Phase)  ANY  • All SAEs  
• All solicited AEs that meet 
Appendix I Vcriteria  
• All unsolicited AEs (Grades 1 to 
4), with the exception of the 
follo wing conditions if not 
treated with prescription medication or non-prescription 
medications with antipyretic properties: diaper rashes, teething 
pain, and spi[INVESTIGATOR_809740]:  
 
• All cough and cold remedies 
including decongestants, cough suppressants, expectorants  
• All nasal sprays (except saline spray)  
• All antihistamines  
• All antip yretics  
• All prescription medications  
 For SAE s and LRIs:  
• All medications related to the 
recorded event  
From the 29th day after inoculation 
to the 56th day after inoculation  
(Post -Acute Phase)  ANY  • All SAEs  
 
 • All medications related to the 
recorded event  
From  Day 56 Visit through start of  
RSV Season Surveillance Period  
 Up to 
October 31 
in year of 
inoculation  • Grade ≥  3 AE s or SAE s that is 
deemed related to Pre- RSV 
Season Study Visit procedures  • All medications related to the 
recorded event  
RSV First and Second Season 
Surveillance Period s November 
1 to March 
31  • Fever s, LRI s, URI s, and/or otitis 
media that are medically attended  
• All SAEs  
 
Note: These events do not need to 
meet the  Appendix IV criteria  For SAE s and LRIs  (all grades) : 
• All medications related to the recorded event  
 
Medications related to recorded 
medically attended illness should 
be documented in source notes  
Post-RSV Season  Ideally 
April 1  to 
April 30 ; 
allowable 
through 
Sept 30th 
in the year 
after the 
inoculation  • Grade ≥  [ADDRESS_1119832] -RSV 
Season Study Visit procedures  • All medications related to the 
recorded event  
Throughout study  ANY  • Unresolved AE s or SAE s with 
onset from  Day 0 to midnight on 
the 28th day after inoculation  
• Unresolved SAE s with onset prior 
to the 56th day following 
inoculation  
• Unresolved SAE s with onset 
during RSV Surveillance Period or related to the Pre - or Post -RSV 
Season Study Visit  • All medications related to the 
recorded event  
 
55 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
   
56 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 
 SERIOUS ADVERSE EVENT REPORTING  
 
All SAEs will be reviewed by a study physician, recorded on the Safety Expedited Report Form (SERF) 
and followed through to resolution. SAEs that have not resolved by [CONTACT_1008] -up period are 
followed until final outcome is known. If it is not possible to obtain a final outcome for an SAE (e.g., the subject is lost to f ollow -up), the reason a final outcome could not be obtained will be recorded by [CONTACT_809809]. In addition to the SAE Reporting Category identified below, 
other AEs that must be reported in an expedited manner are LRI s as defi ned in Appendix IV  if they occur  
during study days 0 to 10 in groups 1 and study days 0 to 28 in group 2.  
 
 
Deaths and imm ediately life-thre atening SAE s will be reported w ithin 1 busi ness day afte r the si te 
becomes aware of the ev ent. All other SAEs will be reported w ithin 3 busi ness day s of site awarene ss. 
SAE s will be reported either by [CONTACT_3719] e- mail to all of the following:  
 
• Sponsor: Office of Clinical Research Policy and Regulatory Operations , NIAID, NIH: Clinical 
Safety Office (CSO) : Phone : [PHONE_070], Fax: [PHONE_016], [EMAIL_007] 
• DSMB Executive Secretary : Phone [PHONE_070], Fax: [PHONE_016], 
[EMAIL_5003] 
• LID, NIAID: Ursula Buchholz, PhD, NIAID/NIH, [PHONE_6783], Fax: [PHONE_6785], 
Email: [EMAIL_6331] 
  
SAEs will also be reported to WIRB (contact [CONTACT_31307]) based on its reporting requirements: 
 
• Western Institutional Review Board (WIRB), [ADDRESS_1119833] SE, Puyallup, WA [ZIP_CODE], Phone: [PHONE_6786] 
 
 REPORTING OF UNANTICIPATED PROBLEMS TO OCRPRO  
 
An UP is defined as any event, incident, experience, or outcome that is: 
1. Unexpected in terms of nature, severity, or frequency in relation to  
a. The research procedures that are described in the IRB -approved research protocol and 
informed consent or other study documents; and 
b. The characteristics of the participant population being studied; and  
2. Possibly, probably, or definitely related to participation in the research; and 
3. Places participants or others at a greater risk of harm (including physical, psychologi cal, 
economic, or social harm) than was previously known or recognized. Per the IND sponsor, an 
AE with a serious outcome will be considered increased risk.  
 
UPs must be reported to the local IRB per their requirements. Non- Serious AEs that are UPs must 
also be reported to the sponsor CSO. Submit the local IRB UP report form to the CSO at the 
following address no later than [ADDRESS_1119834] INFORMATION:  
 
Clinical Safety Office  
[ADDRESS_1119835] Frederick, MD [ZIP_CODE] 
Phone [PHONE_070] Fax [PHONE_016] 
57 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 E-mail: [EMAIL_007]  
 
UPs that are not AEs (UPnonAE) are not routinely reported to  the CSO. However, an UPnonAE  
that may, in the opi[INVESTIGATOR_871], involve risk to the participant, affect others in the research study, or significantly impact the integrity of research data would be considered a non-
serious UP and would be reported to the CSO. For example, we will report occurrences of breaches of confidentiality, accidental destruction of study records, or unaccounted-for study 
drug. 
 
 
 PARTICIPANT MANAGEMENT  
 
 MANAGEMENT OF ADVERSE EVENTS  
 An AE  is any untoward medical occurrence in a participant administered a pharmaceutical 
product that  does not necessarily have a causal relationship with this treatment. An AE can 
therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with  the subject’s participation in the research , 
whether or not related to the subject’s participation in the research . This includes exacerbation of 
pre-existing conditions and intercurrent illnesses.   
 
Causality assessment is based on ava ilable informa tion at the time of the asse ssment of the AE . 
The i nvestigator may rev ise the c ausality assessment as additi onal informa tion becomes 
available. 
 
All AEs identified in this study will be source documented, consistent with the policies and 
procedures referenced in Section  10. Among other details, source documentation will include the 
severity of each event (graded as described in Section s 8.2.[ADDRESS_1119836], assessed by [CONTACT_322142]: 
 
Related  There is a reasonable possibility that the adverse event may be 
related to the study drug. 
 Not related  There is not a reasonable possibility that the adverse event may be related to the study drug.  
 
There are two categories of AEs specific to CIR 32 2: solicited and unsolicited. Solicited AEs are 
described in Section  8.1.1. Unsolicited AEs are all other AEs.  However, for infants and children, 
the following common events will not be recorded as AEs unless a prescribed concomitant medication is used to treat them: non-infectious rashes, teething pain, and spi[INVESTIGATOR_322054]. The use of 
medications will only be captured in the event of an AE or pre -existing condition.
 
 
Serious Adverse Events (SAEs) are described in Section 8.1.2.  
 
58 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119837] protocol- specific 
criteria for reporting.  
 
Solicited AEs, whether identified by a parent/guardian or clinician, are only recorded on CRFs if they me et the definitions per Appendix IV  Individual symptoms listed in the “events” column that 
fail to meet the criteria in the “definition” column in Appendix IV  are recorded in source 
documents but are not recorded on the CRFs. During the Acute Phase of this study, days 0 
through 10 for RSV -seropositive participants and days 0 through 28 for RSV -seronegative 
participants , solicited AEs meeting the criteria for reporting will be recorded on CRFs, assigned a 
severity grade (Section  8.2), and a ssessed for relationsh ip to study product ( see Section  8.1). 
Solicited AEs are defined in Appendix IV  and include the following:  
 1. Fever  
2. URI 
a. Rhinorrhea, 
b. Pharyngitis,  
c. Cough without LRI, or 
d. Hoarseness  
3. Otitis Media  
4. LRI 
a. Wheezing,  
b. Pneumonia, 
c. Laryngotracheobronchitis (croup),  
d. Rhonchi, or 
e. Rales  
 
Solicited AEs Elicited by [CONTACT_809810], solicited AEs reported by [CONTACT_3654]/guardians are NOT recorded on 
CRFs if a clinical assessment done on the day of the event(s) does/did not confirm their presence. For example, if a parent/guardian reports r hinorrhea on the day of visit, and there is/was no 
rhinorrhea upon exam, then the participant is considered to not have rhinorrhea that day. 
 
If the parent/guardian report of a fever meets the “definition” column criteria in Appendix IV  on a 
day on which there was a clinical assessment, the fever will be recorded on CRFs regardless of whether the clinical assessment confirmed its presence.  
 
Events elicited by [CONTACT_7078]/guardian history for days on which there was no clinical exam will be: 
 
1) Recorded on the CRFs as AEs if the parent/guardian description meets the “definition” 
column criteria in Appendix IV . 
2) Recorded only on the source document, and NOT on the CRF, if the parent/guardian description fails to meet the “definition” column criteria in Appendix IV . For example, both 
rhinorrhea and cough must each occur on 2 consecutive days to meet the definition required 
for reporting per Appendix I V. 
59 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119838] or not, tha t meets  one or more 
of the following criteria : 
1. Results in death during the period of protocol -defined surveillance . 
2. Is life threatening: defined as an event in which the participant was at immediate risk of death 
at the time of the event; it does not refer to an event that hypothetically might have caused 
death were it more severe. 
3. Requires inpatient hospi[INVESTIGATOR_059] (or prolongation of existing hospi[INVESTIGATOR_059]): defined as at least an overnight stay in the hospi[INVESTIGATOR_870] . 
4. Results in a persistent or significant disability/incapacity . 
5. Is a congenital anomaly or birth defect. 
6. Is an important medical event that may not be immediately life threatening or result in death 
or hospi[INVESTIGATOR_809741]. 
 
8.1.[ADDRESS_1119839] ed in the Inve stigator ’s Brochure o r Package Insert (for 
marketed products) or is not listed at the specif icity or severity that ha s been observed. 
It is the responsi bility  of the IND Sponsor to make this determina tion. 
 
 GRADING THE SEVERITY OF ADVERSE EVENTS  
 
The Inve stigator will assess all AEs with respe ct to Seriousness (cr iteria listed above), Se verity 
(intensity or grade), and Cau sality (relationship  to st udy agen t and rela tionsh ip to research).   All 
AEs and fever will be graded using the protocol -defined grading system.  
 
8.2.1 AE Grading  
 
Table 21: Grading for Adverse Events  
Severity  Defined  
Grade 1 Mild  No medical intervention required; may include over-the-counter medications 
managed by [CONTACT_809811] 2 Moderate  Outpatient medical intervention by a health care provider required; may include 
use of over -the-counter and/or prescription medications  
Grade 3 Severe  Prolonged medical intervention and/or hospi[INVESTIGATOR_809742] 4 Life threatening  Illness requiring hospi[INVESTIGATOR_809743] 5 Death  Event resulting in fatal outcome to the participant  
 
60 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 8.2.2 Fever Grading  
    
Table 22: Grading for Fever  
Severity  Defined  
Grade 1  ≥100.4ºF but ≤101.4ºF  
Grade 2  ≥101.5ºF but ≤102.4ºF  
Grade 3  ≥102.5ºF but ≤104.8ºF  
Grade 4  ≥104.9ºF  
Applies to any modality of temperature measurement  
 
 PAUSING AND STOPPI[INVESTIGATOR_809744] a participant  during the specified period after receiving  the study 
product, additional enrollment/inoculations will be temporarily suspended at all sites ( Table 23). 
 
Table 23: Pausing and Stoppi[INVESTIGATOR_809745] -Acute 
Days [ADDRESS_1119840] . A description of the vaccine -associated 
AE(s)  or safety issue must be reported by 
[CONTACT_978] [INVESTIGATOR_179167], within one business 
day of the PI's awareness, to the CSO and 
the DSMB by [CONTACT_40743]. 
 
Acute  Only 
Days 0 through 10 
following inoculation 
for RSV -seropositive 
subjects and  days 0 
through 28 following 
inoculation  for RSV -
seronegative subjects  An LRI per Appendix IV , OR  
A fever of Grade 4 OR  
Any Grade 3 or above solicited AE (other than fever)  
 
The regulatory sponsor (OCRPRO) will determine if the FDA needs to be notified. The DSMB 
and regulatory sponsor will be informed and receive pertinent data of the event by [CONTACT_978] . Follow-
up visits for participants already inoculated will continue as outlined in Appendix II  (Table 30).  
 
If the event is determined to have occurred in a participant who received active agent (vaccine), 
and the event meets one of the following stoppi[INVESTIGATOR_585840], then the event will be reviewed by [CONTACT_322145].  
61 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
  
1. One or more participant s experience an SAE that cannot be attributed to an etiology or cannot 
be attr ibuted to a cause unrelated to the study vaccine, OR   
2. One or more participant s develop LRI associated with shedding of vaccine virus at the time 
of the LRI (even if another pathogen is identified, unless the RSV is confirmed to be wt 
RSV), OR  
3. One or more participant s develop LRI that is not explained by a diagnosis unrelated to the 
vaccine virus, OR  
4. One or more participant s experiences a Grade 4 fever or any Grade 3 or Grade 4 solicited AE 
other than fever associated with shedding of vaccine virus, OR 
5. Any pattern of research laboratory values or clinical symptoms is observed that the protocol 
team considers a significant safety issue for participants.  
 The DSMB will notify the PI (via the study sponsor) of their recommendations as to whether  
enrollment can resume, or if the study needs to be stopped.  The regulatory s ponsor (OCRPRO) 
will be informed about this decision.  In the event of an SAE, the study may be resumed if it can 
be demonstrated to the DSMB that there is no proven causal relatio nship with the vaccine. 
 
 STATISTICAL CONSIDERATIONS  
 
 GENERAL DESIGN ISSUES  
 
9.1.1 General Design  
 
The goal of this phase I, blinded, randomized, placebo- controlled vaccine trial is to assess the 
safety, infectivity, and immunogenicity of the  RSV 6120/∆NS2/1030s vaccine candidate in 
RSV- seropositive and RSV -seronegative pediatric participant s. Fifteen RSV -seropositive 
participants will be randomized in a 2:1 ratio to receive either the candidate vaccine at a dose of 10
5.7 PFU or placebo. Twenty -one to thirty RSV-seronegative participants will be randomized in a 
2:1 ratio to receive either the candidate vaccine at a dose of 105.0 PFU or placebo .   
 
9.1.2 Description of the Statistical Methods to be Employed  
 
This study, like other phase I studies, is exploratory, rather than confirmatory; its purpose is to 
assess frequencies of AEs and patterns of immune responses. Descriptive approaches will be used 
to meet the protocol objectives as stated in Section 2 of this prot ocol, as well as formal statistical 
tests as outlined in Section  9.5.  
 
 OUTCOME MEASURES  
 
9.2.1 Primary Outcome Measures  
 
Safety: Types and grades of study product- related:  
• Solicited AEs as defined in Appendix IV  from Study Day s 0-10 for RSV-seropositive and 
Study Days 0-28 for RSV -seronegative participants  
• Unsolicited AEs from Study Days 0-10 for RSV-seropositive and Study Days 0-28 for RSV-seronegative participants  
• SAE (Section 8.1.2 ) from Study D ays 0-28 for RSV- seropositive and Study Days 0-56 for 
RSV-seronegative participants 
62 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
  
Infectivity:  
• Infection wi th RSV as defined as  
1) vaccine virus identified in a nasal wash from Study Days 0-10 for RSV-
seropositive and Study Days 0-28 for RSV -seronegative (a binary outcome based 
on nasal washes done throughout the study period; Day 0 nasal wash will be counted as baseline) ; or  
2) ≥4-fold rise in RSV neutralizing antibody titer from Study Days 0- 28 for RSV -
seropositive and Study Days 0-56 for RSV- seronegative subjects  
• Peak titer of vaccine virus shed from Study Days 0-10 for RSV-seropositive and Study Days 
0-28 for RSV- seronegative subjects 
• Duration of virus shedding in nasal washes as determined by a) culture and b) RT- PCR from 
Study Day s 0-10 for RSV-seropositive and Study Days 0-28 for RSV-seronegative subjects  
 
Immunogenicity: 
• ≥4-fold rise in RSV-neutralizing antibody titer from study entry to Study Day 28 for 
RSV-seropositive and from study entry to Study Day 56 for RSV-seronegative subjects  
• ≥4-fold rise in IgG a ntibody re sponses to RSV F glycoprotein (ELISA) from study entry to 
Study Day 28 for RSV- seropositive and from  study entry and Study Day 56 for RSV-
seronegative subjects  
 
9.2.2 Secondary  Outcome Measures  
 
• The frequency and severity of symptomatic, medically attended respi[INVESTIGATOR_809746]- seronegative ( group 2) vaccine and placebo recipi[INVESTIGATOR_809747] 2 subjects who participate in a second  RSV season surveillance.  
• The antibody responses in the RSV-seronegative vaccine and placebo recipi[INVESTIGATOR_809748] a second  
RSV season for those who choose to participate.  
• The quality and epi[INVESTIGATOR_76802] o f RSF F-specific antibody 
 
 SAMPLE SIZE AND ACCRUAL  
   
9.3.1 Sample Size and Randomization  
 
In group 1, approximately 15 RSV -seropositive children will be enrolled in the study and will 
receive either 105.7 PFU of vaccine or placebo, at a ratio of 2:1.  In group 2, a pproximately 21 -30 
RSV-seronegative infants and children will be enrolled in the study and will receive either 105.0 
PFU of vaccine or placebo at a ratio of 2:[ADDRESS_1119841] experience with phase I 
evaluation of other live-attenuated respi[INVESTIGATOR_322031] ( 24-26 ). The 2:1 
randomization ratio will be used to maximize the information obtained regarding the response of 
children to the RSV 6120/∆NS2/1030s vaccine.  In the event that a participant is discontinued 
early from the study and the team decides that additional data would be needed to answer the study objectives, an additional participant may be enrolled in the same treatment arm as the 
discontinued participant. 
 
63 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 Eligible subjects whose parents/guardians decline participation in the second RSV season 
surveillance will not be replaced.  
 Given the small sample size, the study will have limitations with respect to detecting AEs and 
estimating the rates of such events in the population represented by [CONTACT_809812].  The following calculations focus on the assessment of the tolerability of the vaccine and, in 
particular, occurrence of LRI, which occurs very infr equently in children who participate in these 
types of studies but would be considered a sentinel safety event if observed in children infected with vaccine virus.   
 Table 24 shows the probability of observing 0 events of LRI within the sample of 20 seronegative 
vaccinees, as well as the probability of observing 1 or more events or 2 or more events, under a 
range of assumptions concerning the true rate of such events in the participant  population 
represented by [CONTACT_809813] . From this table, it can be seen that if the true proportion of LRI (or 
other AE) is at least 10%, there is a 61% chance of observing 2 or more events in a group of size 
20, and an 88% chance of observing at l east a single event.  
 
Table 24: The Probability of Observing LRI Events in Seronegative Vaccine 
Recipi[INVESTIGATOR_840]  
 N = 20 
True underlying probability 
of LRI or AEs  Pr (0 
events)  Pr (1+ 
events)  Pr (2+ events)  
.01 0.82 0.18 0.02 
.03 0.54 0.46 0.12 
.05 0.36 0.64 0.26 
.1 0.12 0.88 0.61 
.15 0.04 0.96 0.82 
 
Table 25 presents 90% confidence intervals (CIs) around potential rates of LRI or AEs that might be observed in the sample of 20 vaccine recipi[INVESTIGATOR_840]. The CIs around similar rates in a sample of 10 
placebo recipi[INVESTIGATOR_809749]. Note that if no LRI or AEs are detected among the 20 
vaccine recipi[INVESTIGATOR_840], we are 90% confident that the true probability of AEs in the population from 
which the sample is drawn is between 0 and 14 %. 
 
Table 25: Percent of Participants Experiencing LRI or AEs with Exact 90% CI  
N % LRI or AEs  90% CI  
10 0% 0% -- 26% 
20 0% 0% -- 14% 
10 10% 1% -- 39% 
20 10% 2% -- 28% 
10 20% 4% -- 51% 
20 20% 7% -- 40% 
10 30% 9% -- 61% 
20 30% 14% -- 51% 
 
64 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 Group sample sizes of 20 in the vaccinated group and 10 in the placebo group would achieve 
80% power to detect a difference between the group proportions of about 0.45. The test statistic 
used is the one-sided Fisher's exact test. The alpha level of the test was targeted at 0.05.   Table 
26 presents examples of true group differences which can be detected with 80% power, and Figure 5 graphically shows power curves for 90% power, 80% power, and 70% power given the 
sample sizes.  
 
Table 26: Magnitude of Difference in Responses Detectable with 80% Power  
Response Proportion in the 
Placebo Group  Response Proportion in 
the Vaccinated Group  Difference  
0.05 0.52 0.47 
0.1 0.59 0.49 
0.15 0.65 0.50 
0.2 0.71 0.51 
0.5 0.95 0.45 
  
 
Figure 5: Power Curves for Assessment of Vaccine Virus Shedding in RSV Seronegative 
Vaccinees  
 
 
   (Alpha=.05; N Vaccine=20; N Placebo=10; 1-Sided Exact Test)  
 
With a sample size of 20 seronegative vaccine recipi[INVESTIGATOR_840] , the 90% CI around a sample mean peak 
titer of 2.5 log 10, with a SD of 1.5 (from IMPAACT 2000)  is (1.92, 3.08). This ensures with 90% 
Response proportion in the Vaccine Group  
65 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 confidence that the true population mean peak titer is between 1.92 and 3.08 log 10, and with 95% 
confidence that the true population mean is not lower than 1.92 log 10. 
 
With the same sample size of 20, the 90% CI around a proportion of 18/20 (90%) vaccine 
recipi[INVESTIGATOR_809750] (72%-98%). For a proportion of 19/20 (95%) the 90% CI is 
(78%-99.7%), and for 20/20 (100%) the 90% CI is (86%-100%). For the target proportion of 
95%, this ensures with 95% confidence that the true proportion of vaccine recipi[INVESTIGATOR_809751] 78%. 
 
 MONITORING  
 
9.4.1 Site Monitoring Plan 
 
As per International Conference on Harmonisation Good Clinical Practice (ICH -GCP ) 5.18 and 
FDA 21 CFR 312.50, clinical protocols are required to be adequately monitored by [CONTACT_30292]. This study monitoring will be conducted according to the “NIAID Intramural Clinical 
Monitoring Guidelines.” Monitors under contract to the NIAID/OCRPRO will visit the clinical 
research site to monitor aspects of the study in accordance with the appropriate regulations and 
the approved protocol. The objectives of a monitoring visit will be: 1) to verify the existence of signed informed consent documents and documentation of the ICF process for each monitored 
subject; 2) to verify the prompt and accurate recording of all monitored data points, and prompt 
reporting of all SAEs; 3) to compare CRIMSON data abstracts with individual subjects’ records 
and source documents (subjects’ charts, laboratory analyses and test results, physicians’ progress 
notes, nurses’ notes, and any other relevant original subject information); and 4) to help ensure investigators are in compliance with the protocol. The monitors also will inspect the clinical site 
regulatory files to ensure that regul atory requirements (Office for Human Research Protections, 
OHRP), FDA, and applicable guidelines (ICH -GCP) are being followed. During the monitoring 
visits, the investigator (and/or designee) and other study personnel will be available to discuss the 
study progress and monitoring visit.  
 
The investigator (and/or designee) will make study documents (e.g., consent forms, CRIMSON data abstracts) and pertinent hospi[INVESTIGATOR_322871], the FDA, the site moni tors, and the NIAID staff for confirmation of the study data.  
 
A specific protocol monitoring plan will be discussed with the PI [INVESTIGATOR_894]. The plan will outline the frequency of monitoring visits based on such factors as 
study enrollment, data collection status and regulatory obligations. 
 
9.4.[ADDRESS_1119842] twice a year or on a schedule specified by [CONTACT_809814], the adherence to the protocol, and AE data. Cumulative safety data (pooled across arms, with the vaccine and placebo arms presented 
together) will be submitted to  the DSMB Executive Secretary for DSMB review. The DSMB 
Executive Secretary will provide the PI [INVESTIGATOR_322065], and the official 
DSMB Report will then be provided in a timely fashion through the office of the NIAID Clinical 
66 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 Director. Th e PI [INVESTIGATOR_322066]. All 
SAEs, LRIs, UPs and IND safety reports will be reported by [CONTACT_978] [INVESTIGATOR_809752]/or regulatory s ponsor (OCRPRO) . The PI [INVESTIGATOR_809753]. The PI [INVESTIGATOR_809754] a pausing or halting criteria are met and obtain a recommendation 
concerning continuation, modification, or termination of the study.    
 ANALYSES  
 
9.5.[ADDRESS_1119843] some missed visits. In the immunogenicity analyses, those who do not provide data for the Day 28 Visit 
follow-up for RSV-s eropositive participants and for the Day 56 Visit follow-up for  
RSV-seronegative participants (due to early discontinuation or missed visit) will be treated as 
“failures .” Sensitivity analyses will be performed to check if the results are consistent with those 
when these participants are excluded. Participants who receive any of the disallowed treatments 
listed in Section  5.[ADDRESS_1119844] 56 days after inoculation for RSV-seronegative partic ipants  may be excluded 
from the immunogenicity evaluations after the time of the treatment. These participants , however, 
will be included in the safety evaluations for the duration of the study. These participants wil l not 
be replaced. Details of the analyses listed below will be included in the statistical analysis plan.   
 
The frequency of solicited AEs and unsolicited AEs, along with 90% confidence intervals, during 
Study Days 0 to 10 in RSV -seropositive subjects and during Study Days 0 to 28 in RSV-
seronegative subjects  and of vaccine-related SAE during Study Days 0 to 28 in RSV-seropositive 
subjects and during Study Days 0 to 56 in RSV- seronegative subjects will be summarized. In 
addition, line listing of individual clinical solicited AEs and unsolicited AEs, graded by [CONTACT_926], 
will be prepared for events occuring during Study Days 0 to 10 in RSV- seropositive subjects and 
during Study Days 0 to 28 in RSV- seronegative subjects and vaccine-related SAE during Study 
Days 0 to 28 in RSV -seropositiv e subjects and during Study Days 0 to 56 in RSV- seronegative 
subjects. 
 
The proportion of participants with infection defined as recovery of vaccine virus from a nasal 
wash as determined by [CONTACT_809815] -PCR, and/or a >4- fold rise in neutralizing antibody titer to 
RSV, will be summarized. A line listing of the individual peak titer of vaccine virus shed and 
duration of virus shedding in nasal washes by [CONTACT_322149]. In addition, the geometric mean peak titer and mean duration of virus shed will be provided for each treatment 
group.  
 The proportion of participants that develop 4- fold or greater rises in RSV -neutralizing antibody 
titer following vaccination will be summarized. A line listing of the individual RSV antibody titer 
pre- and post-vaccination will be prepared. In addition, the geometric mean and median antibody 
titers will be provided for each treatment group. Line listings of individual RSV-neutralizing 
antibody responses as well as of antibody responses to the RSV F glycoprote in will be prepared 
as well.  
 Where appropriate, a [ADDRESS_1119845] the hypothesis that the 
vaccinated group will exhibit greater peak viral titers and antibody titers following vaccination compared to the placebo group. A 1- tailed Fisher’s exact tes t will be used to test the hypothesis 
67 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 that the vaccinated group will exhibit a greater proportion of participants who develop fourfold or 
greater rises in RSV -neutralizing antibody titer following vaccination compared to the placebo 
group.   
These will be the only formal statistical comparisons between the vaccinated and placebo groups. 
These tests will be carried out at a 5% significance level.  
 
The study results will be compared with the criteria listed in Section  1.[ADDRESS_1119846]. 
Corrections to the data system shall be tracked electronically (password protected) with time, 
date, individual making the correction, and what was changed.  
 
Source documents include all recordings of observations or notations of clinical activities, and all reports and records necessary for the evaluation and reconstruction of the clinical trial. Source 
documents may include the subject’s medical records and laboratory reports. Data will be 
collected directly from subjects during study visits and contacts.   
 
68 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 
 ESSENTIAL AND SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA 
 
Study-related documentation will be completed as required by [CONTACT_1201], the sponsor, and 
regulatory authorities. Continuing review documentation will be submitted to the IRB as 
specified by [CONTACT_1201]. An annual report will be submitted by [CONTACT_809816] 6120/∆NS2/1030s vaccine went into effect. These 
reports will provide a brief description of the progress of the investigation as outlined in [ADDRESS_1119847] be accessible for inspection, mo nitoring, and/or auditing during and after 
the conduct of the study by [CONTACT_809817], the FDA, regulatory authorities, IRB, OHRP, and other applicable regulatory entities. 
Records must be kep t on-site throughout the period of study implementation ; thereafter, 
instructions for off -site storage may be provided by [CONTACT_4289]. No study records may be removed to an 
off-site location or destroyed prior to receiving approval from NIH.  
 
Study- related documents will be maintained for a period of at least [ADDRESS_1119848] (or longer based upon local laws). The sponsor  is required to  inform 
the PI  [INVESTIGATOR_322071]. No study document should be 
destroyed without prior written agreement between the sponsor and the PI . Storage of all study-
related documents will be such that confidentiality will be stri ctly maintained. These records are 
also to be maintained in compliance with IRB, state, and federal medical records retention requirements, whichever are longest. Should the PI [INVESTIGATOR_809755]/or move them to another location, the PI [INVESTIGATOR_809756]/or their new location. The sponsor must be notified in writing, and written permission 
must be received from the sponsor prior to destruction or relocation of research records. 
 
 CLINICAL INVESTIGATOR ’S BROCHURE  
 
The current version of the IB comprehensively describes all the available preclinical experience 
with the experimental v accine. If relevant new information becomes available during the course 
of the trial, the PI  [INVESTIGATOR_229954] a revised IB or an amendment to the current version.  
 
 QUALITY CONTROL AND QUALITY ASSURANCE  
 
Essential documents and participant research records are subject to continuous quality control and 
quality assurance procedures consistent with  the MOP.  
 
 CLINICAL SITE MONITORING  
 
Site monitors under contract to NIAID will inspect study facilities and revie w participant study 
records including ICD, CRFs, medical records, laboratory records, and study product records, to 
ensure protection of study participants, compliance with the IRB  approved protocol, and accuracy 
and completeness of records. The monitors a lso will review essential document files to ensure 
compliance with all appli cable regulatory requirements. Study staff w ill make study facilities and 
documents available for inspection by [CONTACT_85231].    
The sponsor will retain originals of the Form FDA 1572 and copi[INVESTIGATOR_322073].  
69 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119849] monitoring will be conducted according to the OCRPRO Clinical Trial Management Group’s Monitoring Plan.  
 HUMAN SUBJECTS PROTECTIONS  
 
 INSTITUTIONAL REVIEW BOARD /ETHICS COMMITTEE REVIEW AND APPROVAL  
 Prior to study initiation, the PI [INVESTIGATOR_809757] s in 
accordance with [ADDRESS_1119850] be maintained in the essential document files.  
 A copy of the study approval (including approval of the ICD ) is to be maintained in the 
investigator’s study document binder, and a copy will be supplied to the sponsor.  
 
During the study, the PI [INVESTIGATOR_322075] 
(i.e., protocol amendments, ICD  updates, advertisements, and any written information that may 
be provided to the participant’s parents/guardians). Study progress reports  will be made to the 
IRB by [CONTACT_322153]. 
 
 VULNERABLE PARTICIPANTS  
 
The NIH is mandated by [CONTACT_809818] ( 40, 41). This study responds to that mandate and will provide clinical research data 
to inform RSV vaccine infectivity, safety and immunogenicity in children. Nonetheless, the infants who take part in this study are considered vulnerable participants per the US C FR, and site 
IRBs/IBCs must consider the potential risks and benefits to child participants as described in 45 
CFR 46 Subpart D (for children). 
 
 INFORMED CONSENT  
 
In obtaining and documenting informed consent, the PI  [INVESTIGATOR_809758], ICH -GCP guidelines, and ethical principles. The written ICD  must be 
approved by [CONTACT_322154]. 
 
Written informed consent for study participation will be obtained before any study- specific 
procedures are performed . The informed consent process will include information exchange, 
detailed discussion, and assessment of understanding of all required elements of informed consent, including the potential risks, benefits, and alternatives to study participation.  
  As part of the in forme d consent process, parents/guardians will also be asked whether they agree 
to storage and future research testing of the biological specimens that remaining after all protocol-
specified testing has been completed. F uture research testing of residual specim ens may be 
declined with no impact on other aspects of study participation.   
70 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119851] infections with wt RSV that circulates in the community. It is hoped that information gained in this study will co ntribute to the development 
of a safe and effective vaccine for the prevention of illness associated with RSV infection.  
 Parents/guardian may be offered child safety seat educational material and referral to community 
inspection stations by [CONTACT_464], and may be offered certified lactation counseling services, if 
appropriate.  
 POTENTIAL RISKS  
 
12.5.[ADDRESS_1119852] care in well child ren and are not usually performed on ill 
children, although many parents are advised to use over-the- counter saline solutions and/or nasal 
bulb suction to clear a young child’s congested nostrils during an URI. The nasal bulb suction and saline- like soluti ons are [ADDRESS_1119853]  
 
If the  study vaccine is insufficiently attenuated, participants could ex perience rhinorrhea, cough, 
fever, otitis media, or LRI. Immediate hypersensitivity reactions including urticaria, anaphylaxis, or other immunoglobulin E ( IgE)-mediated responses are possible, as with any vaccine. With any 
investigational vaccine, there is  a theoretical possibility of risks about which we have no present 
knowledge. Parents/guardians will be informed of any such risks should further data become available.  
 The study participant’s  family does not pay for the study product or research visits including 
examinations and laboratory tests that are part of this study, including evaluation of illness, if any. 
NIAID agrees that the funding for appropriate acute care will be provided through the NIAID 
71 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119854] (HHS272200900010C) for any side effects th at are determined to be related to the 
administration of vaccine.  
 
 REIMBURSEMENT /COMPENSATION  
 
12.6.1 Study Compensation: Acute Phase and First Season Surveillance  
 
Compensation will be in the form of either check or gift card. Participants’ parent/guardian will receive compensation at the rate of  $50 for the inoculation visit, $30 per each scheduled or 
unscheduled study visit , $5 per each scheduled non- visit day repo rt and weekly surveillance 
report, and a $50 bonus for study completion. In addition, the parent/guardian will receive bus 
tokens, taxi fare , or parking passes as needed for study visits. Parent/guardian will be compensated 
only for those portions of the s tudy that are completed. Compensation will be in accordance with 
IRB policies and procedures and will be subject to IRB approval.  
Participant s may receive age- appropriate books or small toys. The total value of the books or toys 
will not exceed $10 per pa rticipant.  
 
12.6.2 Study Compensation: Second Season Surveillance  
 
Subjects’ parent s/guardians will receive compensation at the rate of $50 for the enrollment visit, 
$30 per scheduled or unscheduled study visit, $5 per weekly surveillance report and a $[ADDRESS_1119855] 
participant privacy and confidentiality to the extent possible. Participant information will not be 
released without written permission to do so except as necessary for review, monitoring, and/or 
audit ing as described in Section  9.[ADDRESS_1119856] identification numbers to personal 
identifying information should be stored in a separate, locked location in an area with limited 
access.   
 
 MANAGEMENT OF INCIDENTAL FINDINGS  
 
Study clinicians will inform parents /guardians of all clinically meaningful physical ex am findings 
and laboratory tests. When applicable, study clinicians will provide referrals to non -study sources 
of medical care for further evaluation and/or treatment of these findings.  
 
 ADMINISTRATIVE PROCEDURES  
 
 REGULATORY OVERSIGHT  
 
CIR 322 is sponsored by [CONTACT_809819], Division of Clinical Research, NIAID , NIH. 
72 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119857] the protocol and the protocol ICDs approved, as appropriate, by [CONTACT_9918]/IBC, 
local IBC, and any other applicable regulatory entity.  
 
For any future protocol amendments, upon receiving final IRB/IBC and any other applicable regulatory ent ity approvals, CIR should implement the amendment immediately.  
 
 STUDY IMPLEMENTATION  
 
This study will be conducted in accordance with the protocol, ICH guidelines, and all applicable 
local and US regulations. Study implementation will also be guided by [CONTACT_1758]- specific MOP  
and other study implementation materials.  
 
 PROTOCOL DEVIATION REPORTING  
 Protocol deviations must be documented in participant research records. Reasons for the 
deviations and corrective and preventive actions taken in response to the deviations should also be documented. See MOP for further instructions.  
 
Deviations will be reported to the IRB and other applicable review bodies in accordance with the 
policies and procedures of these review bodies. Serious deviations that are associat ed with 
increased risk to one or more study participants and/or significant impacts on the integrity of study data must also be reported following procedures specified in the MOP .  
 
 CLINICAL TRIALS .GOV 
 This protocol is subject to the US Food and Drug Administration Amendments Act of 2007 
(FDAAA), including registration in ClinicalTrials.gov.  
 
 PUBLICATIONS  
 Publication of the results of this trial will be governed by [CONTACT_809820]. Any presentation, abstract, or manuscript will be made available for review by [CONTACT_809821]. Publication or presentation approval will conform to any 
Cooperative Research and Development Agreement (CRADA) or other collaborative agreement 
in place.  
  
73 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 
 REFERENCES  
 
1. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, 
Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. 2009. The burden of respi[INVESTIGATOR_153655]. N Engl J Med 360:588-598. 
2. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien 
KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower 
respi[INVESTIGATOR_4432]: a systematic review and meta- analysis. Lancet  375:1545- 1555 . 
3. Hall CB. 2001 . Respi[INVESTIGATOR_316731]. N Engl J Med 
344:1917- [ADDRESS_1119858] DisJ  22:S76-S82. 
5. Collins PL, Karron RA.  2013. Respi[INVESTIGATOR_322079] , 
p 1086- 1123.  In Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin 
MA, Racaniello VR, Roizman B (ed),  Fields Virology, Sixth Edition, Sixth ed , vol 
1. Lippi[INVESTIGATOR_4431] & Wilkins , Philadelphia . 
6. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parro tt 
RH. 1969. Respi[INVESTIGATOR_780115]. Am J Epi[INVESTIGATOR_5541]  89:422-434. 
7. Collins PL, Murphy BR. 2007. Vaccines against Human Respi[INVESTIGATOR_227231]. Respi[INVESTIGATOR_14250]  14:233-278. 
8. Acosta PL, Caballero MT, Polack FP.  2015.  Brief history and characterization 
of enhanced respi[INVESTIGATOR_139095]. Clinical and Vaccine Immunology 23:189-195. 
9. Collins PL, Murphy BR. 2005.  New generation live vaccines agai nst human 
respi[INVESTIGATOR_322081]. ProcAm ThoracSoc  
2:166-173. 
10. Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB, Collins PL, O'Shea AF, Gruber WC, Murphy BR. 2007.  The absence of enhanced disease with wild 
type respi[INVESTIGATOR_322082], attenuated, respi[INVESTIGATOR_129716]. Vaccine 25:7372- 7378.  
11. Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F,  Polack 
FP, Randolph VB, Deatly A, Hackell J, Gruber W, Murphy BR, Collins PL. 2005.  Identification of a recombinant live attenuated respi[INVESTIGATOR_809759]. J Infect Dis 191:1093- 1104.  
12. Hendry RM, Burns JC, Walsh EE, Graham BS, Wright PF, Hemming VG, 
Rodriguez WJ, Kim HW, Prince GA, McIntosh K. 1988. Strain -specific serum 
antibody responses in infants undergoing primary infection with respi[INVESTIGATOR_4345]. J Infect Dis 157:640-647. 
13. Johnson PR, Jr., Olmsted RA, Prince GA, Murphy BR, Alling DW, Walsh EE, 
Collins PL. 1987. Antigenic relatedness between glycoproteins of human 
respi[INVESTIGATOR_322084] A and B: evaluation of the contributions of F and G glycoproteins to immunity . J Virol  61:3163- 3166 . 
74 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119859], Hill MG, Camargo E, Grosfeld H, Chanock RM, Murphy BR.  1995.  
Production of infectious human respi[INVESTIGATOR_4436] 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. ProcNatlAcadSci[LOCATION_003]  92:[ZIP_CODE] -[ZIP_CODE]. 
15. Lo MS, Brazas RM, Holtzman MJ. 2005. Respi[INVESTIGATOR_809760]1 and NS2 medi ate inhibition of Stat2 expression and 
alpha/beta interferon responsiveness. J Virol 79:9315- 9319.  
16. Ramaswamy M, Shi L, Varga SM, Barik S, Behlke MA, Look DC. 2006. 
Respi[INVESTIGATOR_809761] 2 specifically inhibits type I interfe ron signal transduction. Virology 344:328-339. 
17. Spann KM, Tran KC, Chi B, Rabin RL, Collins PL. 2004. Suppression of the 
induction of alpha, beta, and lambda interferons by [CONTACT_282554]1 and NS2 proteins  of 
human respi[INVESTIGATOR_809762] 
[corrected]. J Virol 78:4363- 4369. 
18. Spann KM, Tran KC, Collins PL. 2005. Effects of nonstructural proteins NS1 
and NS2 of human respi[INVESTIGATOR_809763] 3, 
NF-kappaB, and proinflammatory cytokin es. J Virol 79:5353- 5362.  
19. Swedan S, Andrews J, Majumdar T, Musiyenko A, Barik S. 2011. Multiple 
functional domains and complexes of the two nonstructural proteins of human respi[INVESTIGATOR_809764]. J Virol 85:[ZIP_CODE] -[ZIP_CODE] . 
20. Swedan S, Musiyenko  A, Barik S. 2009.  Respi[INVESTIGATOR_809765]. J Virol 83:9682- 9693.  
21. Teng MN, Collins PL. 1999. Altered growth characteristics of recombinant 
respi[INVESTIGATOR_809766]2 protein. J Virol 73:466-
473. 
22. Luongo C, Winter CC, Collins PL, Buchholz UJ. 2012. Increased genetic and 
phenotypic stability of a promising live -attenuated respi[INVESTIGATOR_809767]. J Virol 86:[ZIP_CODE]- [ADDRESS_1119860] Dis 176:1428- 1436.  
24. Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE, Jr., Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE, Casey R, 
Eichelberger M, Thumar B, Randolph VB, Udem SA, Chanock RM, Murphy BR. 2000.  Evaluation of a live, cold- passaged, temperature- sensitive, respi[INVESTIGATOR_809768]. J Infect Dis 182:1331- 1342.  
25. Wright PF, Karron RA, Madhi SA, Treanor JJ, King JC, O'Shea  A, Ikizler MR, 
Zhu Y, Collins PL, Cutland C, Randolph VB, Deatly AM, Hackell JG, Gruber WC, Murphy BR. 2006.  The interferon antagonist NS2 protein of respi[INVESTIGATOR_809769]. J Infect Dis 
193:573-581. 
26. Karron RA, Luongo C, Thumar B, Loehr KM, Englund JA, Collins PL, Buchholz UJ. 2015.  A gene deletion that up- regulates viral gene expression 
75 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 yields an attenuated RSV vaccine with improved antibody responses in children. 
Sci Transl Med 7:312ra175.  
27. Wright PF, Karron RA, Madhi SA, Treanor JJ, King JC, O'Shea A, Ikizler MR, Zhu Y, Collins PL, Cutland C, Randolph VB, Deatly AM, Hackell JG, Gruber WC, Murphy BR. 2006. The interferon antagonist NS2 protein of respi[INVESTIGATOR_809770]. J Infect Dis 193:573-581. 
28. Crowe JE, Jr., Bui PT, London WT, Davis AR, Hung PP, Chanock RM, Murphy BR. 1994. Satisfactorily attenuated and protective mutants derived from 
a partially attenuated cold- passaged respi[INVESTIGATOR_809771]. Vaccine 12:691-699. 
29. Whitehead SS, Juhasz K, Firestone CY, Collins PL, Murphy BR. 1998.  
Recombinant respi[INVESTIGATOR_4345] (RSV) bearing a set of mutations from cold-passaged RSV  is attenuated in chimpanzees. J Virol  72:[ADDRESS_1119861] 
wild-type challenge in seronegative chimpanzees . Vaccine 12:783-790. 
31. Crowe JE, Jr., Firestone CY, Whitehead SS, Collins PL, Murphy BR. 1996. 
Acquisition of the ts phenotype by a chemically mutagenized cold- passaged 
human respi[INVESTIGATOR_809772] a single mutation in the polymerase ( L) gene. Virus Genes 13:269-273. 
32. Whitehead SS, Firestone CY, Collins PL, Murphy BR. 1998. A single 
nucleotide substitution in the transcription start signal of the M2  gene of 
respi[INVESTIGATOR_809773]248/404 is the m ajor 
determinant of the temperature- sensitive and  attenuation phenotypes. Virology 
247:232-239. 
33. Juhasz K, Whitehead SS, Boulanger CA, Firestone CY, Collins PL, Murphy BR. 1999. The two amino acid substitutions in the L protein of cpts530/1009, a 
live-attenuated respi[INVESTIGATOR_809774], are independent 
temperature- sensitive and attenuation mutations. Vaccine 17:[ADDRESS_1119862], Murphy BR. 1997. The temperature -sensitive (ts) phenotype of a 
cold-passaged (cp) live attenuated respi[INVESTIGATOR_809775], 
designated cpts530, results from a single amino acid substitution in the L protein. J Virol 71:5814- 5819.  
35. McFarland EJ, Buchholz UJ, Muresan P, Cunningham CK, Luongo C, Thumar B, Collins P, Perlowski C, Valentine M, Schappell E, 
Gnanashanmugam D, Siberry G, Rexroad V, Barr E, Harding P, DiPerna A, Karron R . High Infectivity of recombinant live -attenuated respi[INVESTIGATOR_809776] ΔM2 -2 in RSV -seronegativeinfants and children, 
manuscript in preparation.    
36. Anonymous. 2007. American Academy of Pediatrics, Committee on Practice 
and Ambulatory Medicine. Recommendations for Preventive Pediatric Health Care. Pediatrics  120:1376. 
76 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          [ADDRESS_1119863] M, Schappell E, Karron RA.  2002.  Comparison of 
temple temperatures with rectal temperatures in children under two years of age. 
ClinPediatr(Phila ) 41:405-414. 
38. Whitehead SS, Juhasz K, Firestone CY, Collins PL, Murphy BR. 1998. 
Recombinant respi[INVESTIGATOR_4345] (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol 72:4467 -4471.  
39. Gharpure MA, Wright PF, Chanock RM. 1969. Temperature- sensitive mutants 
of respi[INVESTIGATOR_4345]. J Virol  3:414-421. 
40. National Institutes of Health.  1994.  Guidelines for the Inclusion of Women and 
Minorities as Subjects in Clinical Research. Federal Register .,  
41. National Institutes of Health.  1998.  NIH Policy and Guidelines on the Inclusion 
of Children as Participants in Research Involving Human Subjects.  
 
 
 
77 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 APPENDICES  
 
APPENDIX I: TABLES REFERENCED IN THE BACKGROUND SECTION 
 
Table 27: Viral Titers of Nasopharyngeal Swab Samples from AGMs Inoculated with the 
Experimental Lot or CTM of RSV 6120/ΔNS2/1030s, with RSV ΔNS2/Δ1313/I1314L, or 
with Recombinant wt RSV rA2  
Virus Test 
Articlea 
and Study 
Number  AGM  
ID NP virus titer (log 10 PFU/mL ) on indicated daysb Peak 
virus  
titer Sum 
of 
daily 
titers c 1 2 3 4 5 6 7 8 9 10 12/ 
14 
RSV rA2 
CTM  
RSV#004Ad 7209  - - 3.1 4.4 4.4 5.2 3.6 4.1 3.4 2.0 - 5.2 31.3 
7467  - 0.7 2.8 3.8 2.1 3.9 3.4 3.2 1.9 2.0 - 3.9 24.5 
7468  - 1.7 2.6 4.0 3.9 3.7 3.6 2.7 3.6 2.6 - 4.0 29.1 
7492  0.7 1.2 2.3 3.9 2.9 3.9 3.9 2.4 1.7 1.0 - 3.9 24.3 
 Mean:             4.2 27.2 
RSV 
ΔNS2/ Δ1313/  
I1314L  
CTM 
RSV#006Ae 7648  - - 1.7 1.2 1.8 2.9 2.2 4.0 3.7 3.4 - 4.0 22.0 
7692  - - - - 1.9 - - 3.3 1.0 1.5 - 3.3 10.2 
7714  - - 0.7 - 1.3 - - 1.4 2.4 2.8 - 2.8 10.7 
7764  - - - 0.7 0.7 1.0 - 2.3 1.2 2.9 - 2.9 10.5 
 Mean :            3.2 13.3 
6120/ΔNS2/  
1030s  
Exp. Lot  8494  - - 2.4 2.4 2.8 3.7 4.1 4.8 >3.3 3.0 - 4.8 28.0 
8542  - - 1.4 2.0 2.0 1.8 2.9 2.9 3.3 1.4 - 3.0 18.5 
8554  0.7 - - 1.5 2.0 2.1 4.1 1.3 3.0 3.6 - 4.1 19.3 
8562  - - - 2.4 3.2 2.9 2.3 1.8 3.2 3.4 - 3.4 20.7 
 Mean :            3.8 21.6 
6120/ΔNS2/  
1030s  
CTM 
RSV#012Af 8928  - 1.7 3.3 3.9 4.1 4.9 3.4 3.6 3.1 1.0 0.7 4.9 30.0 
8940  - - - 1.7 1.5 3.4 0.7 4.3 4.0 3.4 2.2 4.3 22.3 
8983  - - - 0.7 1.5 2.9 2.7 0.7 2.4 1.3 2.7 2.9 15.9 
9045  - 0.7 0.7 1.5 1.3 1.8 3.0 2.6 1.3 - 0.7 3.0 13.8 
 Mean :            3.8 20.5 
a Monkeys were inoculated i.n. and i.t. with 106 PFU of the indicated virus in a 1 mL inoculum per site (total dose =  2x106 
PFU/AGM).  
b Virus titrations were performed on Vero cells. The lower limit of detection was 0.7 log 10 PFU/mL. Samples with no detectable 
virus are represented as “ -“. Peak titers f or each animal are underlined.  
c The sum of daily titers is used as an estimate for the magnitude of shedding (area under the curve). A value of 0.35 was used for 
samples with no detectable virus.  
d Lot RSV#004A , vial numbers 263, 886, 1108, 1567.  
e Lot R SV#006A, vial numbers 0004, 1377, 2505.  
f Lot RSV#012A, vial numbers 0019- 0021, 1267 -1269, 2483 -2486. 
Abbreviations: AGM- African green monkey, CTM - clinical trial material, RSV- respi[INVESTIGATOR_4345], NP - nasopharyngeal, 
PFU - plaque -forming units , i.n.- intranasally, i.t. - intratracheally.  
  
 
78 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 Table 28: Viral Titer of Tracheal Lavage S amples from AGMs Inoculated with the 
Experimental Lot or CTM of RSV 6120/ΔNS2/1030s, with RSV ΔNS2/Δ1313/I1314L, or 
with Recombinant wt RSV rA2  
Virus Test Articlea 
and Study Number  AGM ID  TL Virus Titer (log 10 PFU/mL) on 
Indicated Dayb Peak 
Virus 
Titer Sum of 
Daily  
Titers c 
2 4 6 8 10 12/14    
RSV rA2 
CTM  
RSV#004Ad 7209  3.0 3.8 4.3 4.5 2.6 - 4.5 18.9 
7467  3.0 3.0 4.3 3.4 2.8 - 4.3 17.2 
7468  2.5 1.7 2.9 3.0 2.9 - 3.0 13.7 
7492  1.9 3.5 4.7 3.3 - - 4.7 14.8 
Mean :       4.1 16.2 
RSV ΔNS2/ Δ1313/ 
I1314L  
CTM RSV#006Ae 
 7648  - - - 1.5 - - 1.5 5.0 
7692  - - - 1.0 1.7 - 1.7 5.5 
7714  - - - - - - - 4.2 
7764  - - - 1.3 - - 1.3 4.8 
Mean:        1.4 4.9 
6120/ΔNS2/  
1030s  
Exp. Lot  8494  2.5 3.7 3.8 3.5 3.0 - 3.8 17.2 
8542  - 5.8 4.1 4.5 3.5 - 5.8 19.3 
8554  2.0 1.5 4.3 4.0 3.3 2.1 4.3 17.2 
8562  - 2.4 2.0 4.5 3.3 1.0 4.5 14.0 
Mean :       4.6 16.9 
6120/ΔNS2/  
1030s  
CTM RSV#012Af 
 8928  2.3 1.0 2.0 3.2 1.0 1.0 3.2 9.9 
8940  1.0 3.1 2.9 3.4 2.8 1.0 3.4 13.6 
8983  1.0 1.0 1.0 1.0 1.0 2.1 2.1 5.6 
9045  1.0 2.4 2.7 3.1 2.3 1.0 3.1 12.1 
Mean :       2.9 10.5 
a Monkeys were inoculated i.n. and i.t. with 106 PFU of the indicated virus in a 1 mL inoculum per site (total dose =2x106 
PFU/AGM).  
b Virus titrations were performed on Vero cells. The lower limit of detection was 1.0 log 10 PFU/mL.  Samples with no detectable 
virus are represented as “ -“. Underlined value indicates maximum titer for each animal.  
c The sum of daily titers is used as an estimate for the magnitude of shedding (area under the curve). Values of 0.7 are used for 
samples wi th no detectable virus.  
d Lot RSV#004A , vial numbers 263, 886, 1108, 1567  
e CTM vial numbers 0004, 1377, 2505  
f Lot RSV#012A, vial numbers 0019- 0021, 1267 -1269, 2483 -2486. 
Abbreviations: AGM- African green monkey, CTM - clinical trial material, RSV- respi[INVESTIGATOR_4345], TL- tracheal lavage , 
PFU - plaque -forming units , i.n.- intranasally, i.t. - intratracheally.  
  
 
79 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 Table 29: Serum PRNT 60 Titers in AGMs Inoculated with the Experimental Lot or with 
CTM  of RSV 6120/ΔNS2/1030s or RSV ΔNS2/Δ1313/I1314L, or R ecombinant wt RSV rA2  
 
Virus Test Articlea 
and Study Number  AGM ID  RSV Neutralization Titer      
 (Log2 of reciprocal) on Indicated D ays 
0 21 28 
RSV rA2  
wt RSV 
CTM RSV#004Aa 7638  - 7.0 6.6 
7744  - 6.5 7.9 
7781  - 8.0 8.6 
7799  - 7.6 7.8 
 Mean :  7.3 7.8 
RSV ΔNS2/ Δ1313/ 
I1314L  
CTM RSV#006Ab 7648  - 6.4 6.8 
7692  - 6.6 6.4 
7714  - 4.4 6.1 
7764  - 5.5 6.0 
 Mean : - 5.8 6.3 
6120/ΔNS2/  
1030s  
Exp. Lot  7638  - 9.6 9.7 
7744  - 9.3 9.6 
7781  - 7.5 9.4 
7799  - 8.7 9.4 
 Mean :  8.8 9.5 
6120/ΔNS2/  
1030s  
CTM RSV#012A c 8928  - 6.8 6.8 
8940  - 5.3 5.7 
8983  - 3.3 3.3 
9045  - 5.6 5.6 
 Mean :  5.3 5.4 
a Lot RSV#004A; vial numbers 263, 886, 1108, 1567  
b Lot RSV#006A, vial numbers 0004, 1377, 2505.  
c Lot RSV#012A, vial numbers 0019- 0021, 1267 -1269, 2483 -2486. The lower limit of detection of the 60% Plaque Reduction 
assay is 3.3 (Log 2 of the dilution reciprocal). Samples below the lower limit of detection are recorded  
as “-“.  
Abbreviations: AGM- African green monkey, CTM - clinical trial material, RSV- respi[INVESTIGATOR_4345].  
  
 
80 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 APPENDIX I I: SCHEDULE OF EVENTS: SCREENING, ACUTE PHASE, AND POST -
ACUTE PHASE  
 
Table 30: Schedule of Events: Grou p 1: RSV -Seropositive Participants  
 
 
ACUTE PHASE  POST- ACUTE PHASE   
Screeninga Day 0  Day 1  Day 2  Day 3  Day 4  Day 5  Day 6  Day 7  Day 8  Day 9  Day 10  Day 11  Day 12 -27 Day 28   Illness 
Visit  Early DC  
Study window   ± 1 day   +7 days   
In person visit  X X   X X X X X   X  * X X X 
Non-visit contact    X X      X X  X *    
Informed consent  X                 
History  X                 
Interim history   X X X X X X X X X X X X * X X X 
Physical exam (full)  X                 
Clinical assessment 
(focused PE)   X   X X X X X   X  *  X  
Administer study 
product   X                
Blood for: 
immunologic assays  5mL               5mL   5mL  
Nasal wash and/or 
nasosorption SAM 
strip for: RSV 
antibody   X             X  X 
Nasal wash for:  
viral detection & 
quantification   X   X X X X X   X  *  X X 
Request adventitious 
agent assay               *  X  
Total blood volume  5mL  -- -- -- -- -- -- -- -- -- -- -- -- -- 5mL  -- 5mL  
*If a family reports an SAE that may meet the study pause or stop criteria , complete the indicated tasks  
a Blood for  RSV immunological assay is obtained not more than 56 da ys prior to inoculation . Screening R SV 
antibody can be obtain ed grea ter than 56 da ys prior to inoculation  so long as it is obtained within the same calendar 
year. 
 
81 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 Table 31: Schedule of Events: Group 2: RSV -Seronegative Participants  
 
 ACUTE PHASE  
  
 POST- ACUTE 
PHASE   
Screeninga Day 0  Day 1  Day 2  Day 3  Day 4  Day 5  Day 6  Day 7  Day 8  Day 9  Day 10  Day 11  Day 12  Day 13  Day 14  Day 15  Day 16  Day 17  Day 18 -27 
(contact 
[CONTACT_322156])  Day 28  Day 29  Day 30 -55 Day 56  Illness 
Visit  Early DC  
Study window   ± 1 day    +7 days  
In person visit  X X   X  X  X   X  X  X   X  X  * X X X 
Non-visit contact    X X  X  X  X X  X  X  X X  X  X *    
Informed consent  X                          
History  X                          
Interim history   X X X X X X X X X X X X X X X X X X X X X * X X X 
Physical exam  X) X                         
Clinical assessment 
(focused PE)   X   X  X  X   X  X  X   X  X  *  X  
Administer study 
product   X                         
Blood for: 
immunologic assays  5mL                        5mL   5mL  
Nasal wash and/or 
nasosorption SAM 
strip for: RSV 
antibody   X                   X   X  X 
Nasal wash for:  
viral detection & 
quantification   X   X  X  X   X  X  X   X  X  *  X X 
Request adventitious 
agent assay                        *  X  
Total blood volume  5mL -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 5mL -- 5mL 
*If a family reports an SAE that may meet the study pause or stop criteria , complete the indicated tasks  
a Blood for  screening is  obtained not more than  42 da ys prior to inoculation . 
 
82 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 2.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          15 March 2019  
 APPENDIX II I: SCHEDULE OF EVENTS: RSV SEASONAL S URVEILLANCE 
 
Table 32: Schedule of Events: RSV Seasonal Surveillance  
 Pre-RSV season  Weekly contact  [CONTACT_144214]-RSV season  Illness 
Visit  Early 
DC 
Visit period  Oct 1st to Oct 31st  Nov 1st to Mar 31st Ideally Apr 1st to 
Apr 30th; 
allowable through 
Sept 30th    
Clinical assessment  
(focused PE)     X  
Interim history   X  X X 
LABORATORY EVALUATIONS  
Blood for:  
immunologic assays  5 mL   5 mL   5 mL  
Nasal wash and/or 
nasosorption SAM 
strip for 
immunologic assay  X  X   
Nasal wash for  
viral detection & 
quantification     X  
Request adventitious 
agent assay     X  
TOTAL BLOOD 
VOLUME  5 mL -- 5 mL -- 5 mL 
 
 
83 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 2.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          15 March 2019  APPENDIX I V: DEFINITIONS OF SOLICITED ADVERSE EVENTS  
 
Table 33: Definitions of Solicited Adverse Events  
Event  Defined  
Fever  Temporal or rectal temperatures ≥100.4oF 
Acute Otitis Media1 Loss of tympanic membrane landmarks,  accompanied by [CONTACT_809822]. May or may not be associated with fever or other respi[INVESTIGATOR_1856]. 
Confirmed with tympanometry if possible.  
Upper Respi[INVESTIGATOR_322094] (URI)  
Rhinorrhea  Two or more consecutive days of clear or purul ent discharge from the nares.  
Note: Not associated with crying, change of room temperature, or eating and 
drinking.  
Pharyngitis1 Pharyngeal erythema accompanied by [CONTACT_809823] , tender lymph nodes.  
Note: May be associated with sore throat, or painful or difficult swallowing.  
Cough Without LRI  Two or more consecutive days of 3 or more epi[INVESTIGATOR_322095] a 15 -minute 
timed observation period, or cough awakens child from sleep.  
Note: Not associated with eati ng, drinking or choking.  
Hoarseness  An unnaturally deep or rough quality of voice.  
Lower Respi[INVESTIGATOR_322094] (LRI)  
Wheezing2,[ADDRESS_1119864], usually accompanied 
by [CONTACT_229019], which do not clear with cough. May be confirmed by x -ray showing 
areas of consolidation.  
Laryngotracheobronchitis ( Croup) 
1,2,[ADDRESS_1119865] ethoscope. Rales may be sibilant 
(whistling), dry (crackling) or wet (sloshy) depending on the amount and density of 
fluid refluxing back and forth in the air passages.  
[ADDRESS_1119866] be made by a medical professional and confirmed by a second medical professional, if possible.  
 
NOTE: Solicited AEs will only be recorded on CRFs according to criteria defined in Section 7.2 
 
 
 
84 
RSV 6120/ ∆NS2/1030s, Lot#012A              Version 3.0 
Principal Investigator: [INVESTIGATOR_489258] A. Karron, MD          6 April 2020  
 APPENDIX V: RSV SEASONALITY IN BALTIMORE  
 
Figure 6: RSV Seasonality in Baltimore  
 
 
 
All specimens collected and tested at Johns Hopkins Hospi[INVESTIGATOR_809777] 10 March 2016. 
 
